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 ABSTRACT 
 
Isothiocyanates (ITCs) are natural phytochemicals produced by cruciferous vegetables.  
Recent evidence supports that, in addition to cancer prevention, ITCs can use various 
mechanisms to target malignant cells.  Current therapies for cancer often provoke detrimental 
side effects, however clinical evidence supports that ITCs have little to no side effects in 
patients.  Consequently, ITCs may be a promising treatment option for cancer patients, especially 
patients suffering from head and neck squamous cell carcinoma (HNSCC). 
Despite recent improvements in cancer treatment, overall survival of advanced HNSCC 
has not improved in the past three decades.  Metastasis and chemoresistance represent two 
detrimental events that greatly hinder the outcome for those suffering with HNSCC.  Thus, new 
therapeutic options to enhance survival of patients with advanced HNSCC are needed.  Several 
types of ITCs can be used to target HNSCC, however our studies indicated that benzyl 
isothiocyanate (BITC) elicits the strongest anti-tumor response when targeting chemoresistant 
and metastatic HNSCC cell lines.  
In our in vitro studies, we evaluated the use of BITC as a treatment for HNSCC.  Our 
study had three objectives; the first being to investigate if this compound can prevent HNSCC 
cell migration and invasion, the second was to study if BITC could enhance the effects of 
chemotherapy, and the third was to identify a mechanism through which BITC was eliciting its 
anti-tumor response. 
Our in vitro data suggests that treatment with BITC significantly reduced the viability of 
multiple HNSCC cell lines tested (HN12, HN8, and HN30), but not a normal keratinocyte cell 
line (HAK).  BITC treatments also decreased the migration and invasion of the HN12 cell line, in 
a dose dependent manner, at concentrations that did not affect cell viability.  Additionally, when 
xiv 
 
compared to either BITC or cisplatin treatment alone, the reduction in HNSCC cell viability was 
greater if a pretreatment of BITC was followed by a treatment of cisplatin.  
Furthermore, the expression of the epithelial-mesenchymal transition (EMT) marker, 
vimentin, was significantly reduced after a BITC treatment in the HN12 cell line.  We also 
observed that BITC treatments significantly increased the amount of reactive oxygen species 
(ROS) in HNSCC cells.  Blocking BITC induced ROS with co-administration of catalase or N- 
acetyl-L-cysteine (NAC) significantly inhibited BITC’s ability to prevent cellular migration.  Co-
administration of NAC with BITC prior to cisplatin treatment reduced cytotoxicity as compared 
to BITC pre-treatment followed by cisplatin.  Therefore, indicating that co-administration of 
anti-oxidants with BITC could alter the clinical efficacy BITC.    
Taken together these data suggest that BITC has the capacity to inhibit processes 
involved in HNSCC cell migration and invasion, as well as add to the effectiveness of 
chemotherapy, and both of these events are regulated by BITC induced ROS. 
1 
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ABSTRACT 
 
Isothiocyanates (ITCs) are phytochemicals produced from the hydrolysis of 
glucosinolates, which are found at high concentrations in cruciferous vegetables.  Vegetables of 
the Cruciferae family include broccoli, cauliflower, gardencress, watercress, and cabbage.  A 
number of studies have suggested that the ITCs, sulforaphane (SFN), benzyl isothiocyanate 
(BITC), and phenethyl isothiocyanate (PEITC) are capable of preventing breast, lung, and 
prostate carcinogenesis.  In addition to chemoprevention, SFN, PEITC, and BITC have also been 
investigated for their chemotherapeutic potential in numerous cancers.  The anti-cancer effects 
of SFN, BITC, and PEITC are associated with several cellular pathways that inhibit growth, 
induce apoptosis, and prevent metastasis. 
Studies investigating the chemopreventive and chemotherapeutic properties of SFN, 
PEITC, and BITC are quickly progressing from bench to beside.  This chapter will give a brief 
overview of SFN, PEITC, and BITC, focusing mainly on these ITC’s reported ability to 
inhibit carcinogenesis in vivo and in vitro during three stages: initiation, promotion, and 
progression. 
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INTRODUCTION 
 
Isothiocyanates (ITCs) are phytochemicals produced by vegetables in the Cruciferae 
family [1-3].  Cruciferous vegetables include broccoli, Indian cress, cabbage, Brussels sprouts, 
and watercress [4].  ITCs are generated naturally from the hydrolysis of glucosinolates, which 
are a secondary metabolite found in cruciferous vegetables, and contain a β-D-thioglucose 
group, a sulfonated oxime moiety, and a variable side chain [4].  A cruciferous vegetable 
produces ITCs as a defense mechanism when the plant is damaged or “under attack”.  This 
family of vegetables spatially separates glucosinolates (cytoplasm) from the defense-related 
enzyme myrosinase (external surface of the plant cell wall), and when the plant is damaged or 
chewed the enzyme and glucosinolate are brought into contact, and the glucosinolate undergoes a 
Lossen rearrangement creating the ITC product [5].  The glucosinolate precursor dictates the 
type of ITC produced (Table 1.1).  There are currently over a 100 glucosinolates identified, but 
not all of the corresponding ITCs appear to have anti-carcinogenic properties [2].  Examination 
of the literature suggests that the ITCs most frequently investigated for their anti-cancer 
effects are sulforaphane (SFN), benzyl isothiocyanate (BITC), and phenethyl isothiocyanate 
(PEITC), and are therefore the main focus of this chapter. 
 
Table 1.1 Isothiocyanates with their corresponding glucosinolate precursor and food source. 
Isothiocyanate 
 
Glucosinolate 
(precursor) 
Food Sources 
 Benzyl Isothiocyanate (BITC) 
Phenethyl Isothiocyanate (PEITC) 
Sulforaphane (SFN) 
Glucotropaeolin 
Gluconasturtiin 
Glucoraphanin 
Cabbage, garden cress, Indian cress 
Watercress 
Broccoli, Brussels sprouts, cabbage 
 
All ITCs, including SFN, BITC, and PEITC have the same R-N=C=S structure (Figure 
1.1).  The reactive group is the sulfur containing N=C=S functional group, which is a strong 
4 
 
electrophile and can undergo a nucleophilic attack [6].  The N=C=S group is reported to 
selectively bind to thiol-containing cysteines and ε-amino containing lysines forming 
thiocarbamates and thioureas, respectively [7].   ITCs are suggested to form thiocarbamates 
at a 103  to 104  faster rate than thioureas, but are less stable [6,7].  The ability of ITCs to 
target cysteine residues is significant, because cysteine residues are often found in the catalytic 
site of enzymes [5].  The binding to cysteine residues is suggested to be one way in which ITCs 
can alter signal transduction and redox status [2]. 
 
 
The R group of ITCs varies significantly, and can be either an alkyl or aryl group.  For 
example, SFN contains an alkyl side chain, whereas PEITC and BITC’s side chain is an aryl group 
(Figure 1.1).  Proteomics studies have indicated that the R group may play an important role in the 
targets of ITCs [7,8].  In A549 cells 14C -SFN was shown to bind to only 16 proteins, whereas 14C-
PEITC was shown to target more than 30 proteins [7].  Additionally, a difference in the 
mechanism of action has been reported when investigating PEITC and SFN’s involvement in cell 
cycle and apoptosis [5,6].  Furthermore, PEITC and BITC are reported to inhibit cellular 
 
Figure 1.1  Chemical structure of BITC, 
PEITC, SFN. 
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proliferation, induce apoptosis, and inhibit cellular migration at significantly lower concentrations 
than SFN [3,9-11].  This has also been supported in animal models [2,4,12]. 
Regardless of the mechanism of action, SFN, BITC, and PEITC have all been shown to 
inhibit the growth of many cancerous cell lines, including lung, prostate, and breast [13-17].  
However, when considering an effective treatment for any disease one must assess whether or 
not the treatment is feasible in humans.  Many phytochemicals or polyphenols have indicated 
promising results in cell culture, but the serum concentrations needed to observe similar effects 
in humans has not been achieved.  Studies indicate that the oral bioavailabilities of ITCs are 
high; suggesting that they may be a better treatment option than other phytochemicals.   
The bioavailability of SFN is reported to be high in animals and humans; however there 
is limited data on the oral bioavailability in humans.  In male Wistar rats 82% of SFN has been 
shown to be bioavailable [4,18].  PEITC is also suggested to have a high oral bioavailability in 
both animals and humans [5].  Additionally, the AUC per os (p.o.) and intravenous (i.v.) 
administration of PEITC does not appear to differ significantly in mice and rats [5,18].  
Bioavailability of BITC has only been reported in animals.  More than 98% of [7-14C] BITC was 
rapidly absorbed following oral administration to Wistar rats [19]. 
There are significant differences when comparing the half-life and AUC between the 
different ITCs. The half-life and AUC of SFN is lower than that reported of PEITC.  In humans, 
PEITC has a half-life of 3.7 to 4.9 hours; whereas the half-life of SFN is only reported to be 1.8 
hrs and 1-2 hours, respectively [5,19].  The half-life of BITC in rats is 1-2 hours [19] .  
Interestingly, increasing the dose of PEITC increases the half-life, and decreases the clearance 
[2,4,5].  ITC metabolites are secreted in the urine and the saturation of the enzymes involved in 
the metabolism of ITCs may be an explanation for the decreased clearance [4].  
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Additionally, the accumulation of all ITCs into cells is suggested to be rapid, and the 
intracellular concentration is reported to be several hundred-fold greater than the extracellular 
concentration [2].  This observation has been supported in mouse pancreatic endothelial and 
fibroblast cells, as well as in human prostate and colon cancer cell lines [2,5].  ITCs are also 
reported to reach many tissues because they are coupled to serum albumin and can be 
systemically transported throughout the body and released into tissues [5]. 
When considering the transition from bench to bedside, bioavailability is critical for the 
success of ITCs, but methods to determine ITC concentrations in humans are still being fine-tuned. 
The problem with many of the original methods used for ITC quantification was that they could 
only determine total ITC concentration and not specific ITC conjugates.  Also, the method for 
determining ITC concentration in the urine vs. the blood may need to be different [2,5].  ITCs are 
excreted mainly in the urine; therefore the ITC concentration in the urine is very high.  The 
concentration in the blood is much lower, and the detection method in the serum needs to be more 
sensitive to be able to detect the low levels of ITCs [20].  The test also needs to be specific for a 
particular ITC, not just ITCs in general.  Cyclocondensation is a sensitive test used to detect ITCs; 
however, it can only identify the total ITC concentration [5].  This reaction also cannot distinguish 
between ITCs and other thionyl compounds.  When using blood samples, the cyclocondensation 
reaction is not sensitive enough for ITC quantification.  An assay using polyethylene glycol 
followed by membrane ultrafiltration to remove proteins before high-performance liquid 
chromatography (HPLC) is suggested to be better for ITC identification in blood [5].  Another 
method for ITC quantification, which can be used for both urine and plasma, involves an ammonia 
derivation of ITC to phenethylthiourea and subsequent liquid chromatography/tandem mass 
spectrometry (LC-MS/MS) [5].  The advantage of this method is that it allows specific ITCs to be 
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identified.  This section highlights that, while research on SFN, PEITC, and BITC has come a long 
way, a better understanding of the pharmacokinetics and pharmacodynamics, as well methods of 
detection are still needed to advance the clinical aspects of ITC research. 
Cancer is a multi-stage process involving initiation, promotion and progression and ITCs 
are suggested to target each of these stages.  The objective for the remainder of this chapter is to 
briefly review the evidence for the benefits SFN, BITC, and PEITC treatment in both preventing 
and treating multiple cancer types, as well as a rational mechanism for these effects.   
 
Mechanisms of Action 
The mechanism of action involved in the anti-carcinogenic and anti-tumor activity of 
ITCs have not been fully elucidated.  However, the mechanism involved in ITCs ability to 
inhibit carcinogenesis is more fully understood and involves the inhibition of carcinogen 
activation.  ITCs are known to inhibit the activity of several cytochrome p450s (CYP450), 
which are Phase I enzymes involved in normal metabolism, and also in carcinogen activation 
[1,6,21].  By inhibiting the activity of CYP450s, ITCs can prevent DNA adduct formation and 
the subsequent mutation leading to a transformed cell, thereby preventing carcinogenesis.  ITCs 
also induce certain Phase II enzymes, like GST, through activation of the Keap-1/Nrf2 pathway 
[2,6].  The induction of Phase II enzymes helps dispose of activated carcinogens by transforming 
the carcinogen into a water-soluble compound that can be excreted via the urine [6].  
Additionally, ITC treatments are suggested to rapidly decrease the concentration of reduced 
glutathione (GSH) in cells, which can prevent tumor formation [22].  Hyperplasic cells usually 
have mutations that lead to an increase of reactive oxygen species (ROS) and are sensitive to 
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GSH depletion [23].  A depletion of GSH can induce apoptosis, thereby preventing the 
progression of a pre-neoplastic lesion to a malignant tumor. 
 
 
 
The mechanisms involved in the anti-tumor activity of ITCs are more complex than the 
mechanisms linked to chemoprevention.  In cancerous cells, ITCs target several different 
molecular pathways linked to apoptosis, cell cycle arrest, and migration [2,4,24,25]. However, 
evidence supports that the type of ITC, as well as the concentration, has a significant effect on 
the mechanism of action.  The protein kinase B (AKT), extracellular signal-regulated kinases 
(ERK), and p38 MAP kinase (p38) pathways are frequently discussed in relation to SFN, 
PEITC, and BITC treatment [1,2,4].  Alterations in additional pathways are also linked to ITC 
therapy, as highlighted in Figure 1.2, and will be discussed more thoroughly in the following 
sections [1,2].  
Figure 1.2 Molecular pathways targeted by SFN, BITC, and 
PEITC. 
The anti-tumor activity of these ITCs affect various 
molecular targets that inhibit cell cycle and angiogenesis, 
and induce apoptosis. 
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The mechanism involved in ITC’s ability to trigger apoptosis is complex and therefore 
deserves some discussion.  SFN, PEITC, and BITC induce apoptosis in numerous cancer cell 
lines; however, induction of apoptosis is different between the treatments [4].  PEITC and BITC 
can initiate apoptosis by binding to tubulin [4,7].  Dysfunction of tubulin increases the cleavage 
of caspase-8 and-9.  SFN does not have a strong affinity for tubulin, but does induce ROS more 
potently that PEITC.  SFN, PEITC, and BITC are all shown to decrease the anti-apoptotic 
proteins Bcl-2 and Bcl-xL [4,26].  Additionally, these ITCs induce caspase-3 activity and PARP 
cleavage [1,27,28].  Studies on PEITC suggest that  this  ITC has the ability to stimulate 
caspase-3, -8, and-9 [2].  However, in leukemia cells, it has been shown that caspase-8 is 
critical and caspase-3 only provides a supporting role [29].  Therefore, studies support that 
treatment with ITCs initiate apoptosis through both extrinsic and intrinsic mechanisms.  The pro-
apoptotic protein BID also appears to be cleaved in response to ITC treatment indicating that the 
c-Jun terminal kinase (JNK) pathway is a target of ITCs [4,30].  SFN, BITC, and PEITC, have 
all been shown to target the JNK pathway in various cancer cells.  Interestingly, in OVAR-3 
cells, PEITC suppressed the activation of Akt and ERK1/2, but activated the p38 and JNK1/2 
pathway.   
Treatments with SFN, PEITC, or BITC induce cell cycle arrest, but literature varies on 
the type of cell cycle arrest initiated by each ITC.  SFN and BITC are both reported to induce 
G2/M arrest, while PEITC is reported to induce G0/G1 arrest [25,27,31].  However, these studies 
were done on different cancer cell lines with different concentrations that could account for the 
different results.  In all reported cases, cell cycle arrest after ITC treatment is associated with an 
increase in cyclin-dependent kinase inhibitor 1 (p21/WAF1) and checkpoint kinase 2 (chk2) 
[25,27,31,32].  SFN, PEITC and BITC are also all reported to down-regulate expression of 
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cdc25c, cyclin D1, and cyclin B1 [25,27,31,32].  Additionally, PEITC is reported to down-
regulate cyclin A, and SFN and PEITC are both reported to inhibit cyclin E [3,27,31,32]. 
The mechanisms involved in the inhibition of angiogenesis after ITC treatment are 
associated with some of the same pathways linked to apoptosis induction.  ITCs are known to 
inhibit the Akt pathway, and this pathway activates mTOR, which consequently activates the 4E-
Binding protein (4E-BP).  The 4E-BP regulates expression of HIF-1α.  SFN, PEITC, and BITC 
inhibit HIF-1α expression and subsequently the factors regulated by HIF-1α, which are involved 
in angiogenesis and epithelial-mesenchymal transition (EMT) [17,33,34].  Treatment of prostate 
cancer PC-3 cells with PEITC also decreased expression of the angiogenic factors, epidermal 
growth factor and colony-stimulating factor [24].  PEITC and BITC treatment both cause a 
decrease in the expression of vascular endothelial growth factor (VEGF) [35].   
SFN, PEITC, and BITC have all been shown to inhibit migration and invasion of cancer 
cells in vitro [13,33,34,36,37].  SFN, PEITC, and BITC have also been shown to suppress the 
metastatic potential of breast and NSCLC cells in vivo [38-42].  Suppression of metastasis is 
suggested to occur through modulation of metastasis-related gene expression and inhibition of 
the Akt/ NF-κB pathway.  All three ITCs have been demonstrated to inhibit NF-κB activity in a 
dose dependent manner.  The inhibition of NF-κB activity appears to be a critical target of ITCs, 
in some cancer cell lines.  Inhibition of NF-κB can lead to the inhibition of cell growth, induce 
apoptosis, and inhibit migration.  However, our results suggest that BITC treatment increases 
NF-κBp50 activity in HNSCC cell lines, indicating that the link between NF-κB activity and ITC 
treatment is not clear cut. 
 
11 
 
Uses in Cancer Therapy 
Traditional anti-cancer treatments are associated with debilitating side effects. Using 
ITCs as a chemotherapy or adjuvant therapy is a novel way to target cancer without the 
associated side effects linked to most cancer treatment.  ITC treatments alone are reported to 
inhibit cell growth, induce apoptosis, and decrease metastasis in vivo and in vitro [2].  As an 
adjuvant therapy ITCs sensitize cancer cells to chemo and radiation therapy [28,29,43-47].  ITCs 
also target cancer stem cell (CSC) populations, which are the major cause for cancer recurrence 
and drug resistance [2,43,48].  According to the ‘‘cancer stem cell” theory, tumors are not to be 
viewed as simple monoclonal expansions of transformed cells, but rather as complex tissues 
where abnormal growth originates from a pathological minority of cancer stem cells [48].  These 
cells have maintained stem-like characteristics in that they proliferate very slowly and have an 
inherent capacity to self-renew and differentiate into phenotypically heterogeneous, aberrant 
progeny.  The following sections give a limited overview of studies that have reported the anti-
cancer effects of ITCs in both in vivo and in vitro model systems. 
 
Lung Cancer 
The nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), is found in 
cigarettes and is a major pro-carcinogen linked to lung cancer formation [2].  The results of 
several studies have indicated certain ITCs can inhibit the formation of NNK induced lung 
cancer.  These studies have led to a Phase II clinical trial (NCT00691132), to determine the 
effects of PEITC in participants who smoke only deuterated NNK cigarettes.  The endpoint this 
study is to determine if PEITC consumption affects the urinary levels of NNK biomarkers in 
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current smokers.  This research group will also determine if there are changes in cell 
proliferation or apoptotic bodies in lung biopsies taken after ingesting PEITC or placebo [10].  
 In animal models, SFN and PEITC have both shown to inhibit lung tumor formation and 
progression.  SFN and PEITC both induced apoptosis in lung tissue of A/J mice in which 
cigarette carcinogens had induced a lung adenoma [2,10].  SFN and PEITC also inhibited the 
progression of adenomas to adenocarcinomas in the lung, implying that these treatments are 
useful in lung cancer chemoprevention [2,10].  In cell culture experiments, using various non-
small-cell lung carcinoma (NSCLC) cell lines SFN, BITC, and PEITC have all been shown to 
inhibit cellular proliferation at low concentrations [28,35,49].  Additionally, both SFN and 
PEITC induced apoptosis in A549 lung cells after treatment with 20μM and 40μM of each ITC 
for 24 hours [49].  In several studies PEITC was shown to be a stronger inducer of apoptosis than 
SFN [2].   
PEITC and BITC were reported to reduce migration and invasion of the highly metastatic 
NSCLC cell line, L9981 [35].  This study also demonstrated that BITC and PEITC inhibited 
phosphorylation of AKT, while also inhibiting activity of NF-κB and reducing metastasis related 
gene expression [35].  Additionally, Di Pasqua et al. (2010) showed that pretreatment with 10 
μM of BITC or PEITC sensitized NCI-H596 NSCLC cells to cisplatin [28].   
 
Breast Cancer 
ITC consumption has been linked with a reduction in the risk of breast cancer for some 
time, and has recently been investigated as a breast cancer treatment option [17,21,40].  
Currently, there are three clinical trials recruiting breast cancer patients, all of which are in Phase 
II.  Two studies are to determin if the consumption of broccoli sprout extract (SFN) can alter 
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proliferation of breast tissue (NCT00982319 and NCT00843167).  The study being completed by 
the Shannon lab in Oregon (NCT00843167) is focusing on histone deacetylase (HDAC) activity 
and apoptosis in women diagnosed with breast cancer, ductal carcinoma in situ and/or atypical 
hyperplasia.  Additionally, a clinical trial being sponsored by the Sidney Kimmel Comprehensive 
Cancer Center (NCT00894712) is assessing the protective effects of topical SFN administration 
on radiation-induced dermatitis in women undergoing external-beam radiation therapy for breast 
cancer.   
Several animal feeding studies have indicated that ITC treatment can inhibit breast cancer 
carcinogenesis.  Recently it was published that BITC consumption could inhibit mammary 
carcinogenesis in MMTV-neu mice [34].  The results of this study suggested that a diet 
supplemented with 3mmol BITC/kg of chow could significantly decrease the number of Ki-67 
positive cells and increase the number of apoptotic bodies in mammary tumors [40].   
SFN, BITC, and PEITC are reported to inhibit cell growth and induce apoptosis in breast 
cancer cell lines, such as the MCF-7 cell line [11,49].  Additionally, BITC was reported to inhibit 
epithelial-mesenchymal transition (EMT) in the MDA-MB-231 human breast cancer cell line.  
This was also supported in xenografted human breast cancer cells [39].  Moreover, BITC was 
shown to inhibit hypoxia inducible factor (HIF1-α) expression and activity in MCF-7 cells by 
targeting the 4E binding protein 1 (4E-BP1) [15,17].  
Studies that target cancer stem cells are currently of great interest, and SFN was found to 
decrease the cancer stem cell marker, aldehyde dehydrogenase-1 (ALDH-1), in MCF-7 and 
SUM159 human breast cancer cell lines [50].  Additionally, daily injections of SFN (50 mg/kg) 
for 2 weeks reduced the number of ALDH-1 positive cells by 50% in non-obese/severe 
combined immunodeficient mice with SUM159 xenograft tumors [36].  Treatment with SFN 
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also decreased the number of primary mammospheres, which are known to have cancer stem-like 
cell properties, by 8- to 125-fold in these two cell lines (MCF-7 and SUM159) [50]. 
 
Prostate Cancer 
Epidemiological evidence is mixed when investigating the relationship between 
cruciferous vegetable consumption and prostate cancer.  In eight case-control studies published 
since 1990, the results of four studies showed a significantly lower incidence of prostate cancer 
in men who consumed large amounts of cruciferous vegetable [1,16,21].  The other four studies 
indicated that there was no significant difference.  Limiting the analysis to men who are positive 
for prostate specific antigen (PSA) appears to decrease some bias and show a stronger link 
between ITC consumption and the reduction of prostate cancer [16]. 
A current clinical trial (NCT01265953) is attempting to identify mechanisms by which 
SFN capsules can alter gene expression via epigenetic modifications in patients at risk for 
prostate cancer development.  The investigators are particularly interested in studying SFN’s 
effects on HDAC and DNA methylation in biopsies from men at risk for prostate cancer.  ITCs 
are also reported to target prostate tumors, and there is a Phase II clinical trial (NCT01228084) 
which is recruiting patients with recurrent prostate cancer.  This trial will determine if treatment 
with SFN can decrease PSA levels within 20 weeks of the SFN treatment.   
In addition to the clinical trials, the goals of many in vivo and in vitro studies were to 
investigate ITC’s ability to inhibit and target prostate cancer [1,14,24,30].  Xiao et al. (2010) 
recently published that PEITC can sensitize PC-3 and DU145 cells to docetaxel [51].  In the 
same study, intraperitoneally injected PEITC in combination with docetaxel was shown to up-
regulate pro-apoptotic proteins (Bax and Bak) greater than either PEITC or docetaxel treatment 
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alone in PC-3 xenografts in male athymic mice [51].  Additionally, treatment with PEITC and 
docetaxel combined inhibited average tumor volume significantly more than either treatment 
alone.  One mechanism proposed by which ITCs can exhibit antitumor effects on prostate cancer 
cells is via the JAK/STAT3/IL6 pathway [14,30,35,52].  The results of two independent studies 
have suggested that both SFN and PEITC can inhibit STAT3 activation and IL-6 production 
[15,32].  Inhibition of STAT3 activation is proposed to be one way in which ITCs produce pro-
apoptotic effects [14].  Additionally, BITC treatments were found to inhibit cellular growth and 
induce G2/M cell cycle arrest in DU145 cells [30].  Treatment with BITC also stimulated 
apoptosis in DU145 cells through the release of apoptosis-inducing factor (AIF) and 
endonuclease G (endoG) from the mitochondria, and promoted caspase-3 activation [53]. 
 
Pancreatic Cancer 
Currently, there are no clinical trials investigating the effects of ITCs on the prevention or 
treatment of pancreatic cancer.  However, several animal models have suggested that BITC, 
PEITC, and SFN can inhibit pancreatic tumor formation.  For example, in an animal model using 
Syrian Hamsters, PEITC was shown to inhibit the formation of N-nitrobis (2-oxypropyl) amine 
(BOP)-induced pancreatic tumors [54].  In cell culture, BITC and PEITC are reported to inhibit 
NF-kB activity, STAT3 activation, and induce reactive oxygen species [25,55,56].  Additionally, 
SFN alone or in combination with tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) significantly reduced the growth of pancreatic tumors that are rich in tumor initiating 
cells, or cancer stem cells, while not causing cytotoxic or adverse effects in normal pancreatic 
cancer cells [57].  Rausch et al. (2010) also suggested that SFN in combination with sorafenib 
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has a synergistic effect in targeting pancreatic cancer stem cells, by decreasing clonogenicity, 
spheroid formation, and ALDH1 activity [43]. 
 
Hematological Cancer 
Literature indicates that PEITC has been of significant interest in treating various 
hematological cancers, such as Acute Myeloid Leukemia (AML) and multiple myeloma [2].  A 
Phase I clinical trial (NCT00968461) was scheduled to begin in January of 2012 by the MD 
Anderson Cancer Center.  The objective of the study is to identify the highest tolerable dose 
of orally administered PEITC that can be given to patients who have lymphoproliferative 
disorders and have previously been treated with the drug fludarabine.   
An in vitro study of great clinical interest demonstrated that primary Chronic 
Lymphocytic Leukemia (CLL) cells, both resistant and responsive to fludarabine, were highly 
sensitive to PEITC with an IC50 of 5.4 and 5.1 μmol/L, respectively [29].  However, normal 
lymphocytes did not show sensitivity to PEITC until 27 μmol/L [29].  In other cell culture 
experiments, PEITC treatments inhibit cellular growth and induce apoptosis in the U937, Jurkat, 
and HL-60 human leukemia cell lines [58].   
SFN and PEITC treatments inhibited proliferation of primary human acute myeloid 
leukemia (AML) cells in vivo and in vitro [58,59].  In AML cell lines, both SFN and PEITC 
induced cleavage of PARP and caspases-3 and-9 in a concentration dependent manner [3,60].  
PEITC treatments also inhibited NF-κB, activated the JNK pathway, and inhibited the AKT 
pathway in the U937 human leukemia cell line, indicating a mechanism through which PEITC 
can induce apoptosis [58]. 
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Head and Neck Cancer 
 Studies investigating the effects of ITCs on Head and Neck Cancer are limited.  A few 
epidemiologic and basic research studies have suggested that a diet rich in cruciferous vegetables 
may reduce the risk of developing primary head and neck tumors [61].  As with NSCLC, 
smoking is the biggest risk factor for head and neck squamous cell carcinoma (HNSCC) [62].  
Numerous reports using either animal models and human subjects suggest that ITCs can reduce 
the activity of carcinogens found in cigarettes, such as NNK [54].  All the in vivo studies to date 
have looked at inhibition of lung carcinogenesis in response to cigarette carcinogens.  Future 
studies need to investigate if ITCs can reduce the incidence of NNK induced HNSCC 
carcinogenesis in animal models.   
 However, as with the other cancers, BITC, PEITC and SFN inhibited proliferation of 
HNSCC cell lines in vitro [2,44,61].  BITC also induced caspase-3 and PARP cleavage in the 
UM-22B and 1483 HNSCC cell lines in a time dependent manner [63].  In addition, BITC 
induced rapid activation of p38 MAPK, as well as activation of p44/MAPK in these same cell 
lines [61,63].  Another HNSCC study showed that a combination of SFN and radiation might 
produce a synergistic effect in decreasing proliferation in four HNSCC cell lines [45].  This 
study also indicated that a combination of SFN and chemotherapy increased apoptosis of 
HNSCC cell lines greater than treatment with either SFN or radiation alone.  Data generated in 
our laboratory also suggested that BITC pretreatment sensitizes the highly resistant HN12, HN30 
and HN8 HNSCC cell lines to cisplatin [44].  Additionally, we observed that BITC appears to 
inhibit migration of the HN12 HNSCC cell line in a dose dependent manner (Figure 1.3). 
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Figure 1.3 BITC and PEITC treatments inhibit wound healing in the HN12 cell line. 
(A) Inverted light microscope images of HN12 cells 24 hours after cells were treated with 
BITC (2.5-5µM) for 1-hour.  (B) Inverted light microscope images of HN12 cells 24 hours 
after cells were treated with PEITC (2.5-5µM) for 1-hour.  Dashed lines represent scratch 
size before treatment.  Magnification 100X. 
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Conclusions 
This chapter highlights the chemopreventive and chemotherapeutic potential of SFN, 
PEITC, and BITC.  We discussed in vitro and in vivo data indicating that SFN, PEITC, and BITC 
treatments inhibit cellular proliferation, induce apoptosis, prevent metastasis, and inhibit 
angiogenesis of various cancers.  We also provided evidence that ITCs can chemosensitize cancer 
cells.  Interestingly, evidence also supports the notion that ITCs target cancer stem cells in 
breast, prostate, and pancreatic cancer. Furthermore, results from ITC clinical trials, while 
limited, suggest that the administration of SFN, BITC, or PEITC are safe treatment options and 
clinically relevant concentrations can be achieved.   
The goal of this thesis is to further expand the knowledge of ITCs as a cancer treatment 
option.  This chapter briefly highlighted the use of ITCs in HNSCC, and in following chapters 
we will present further results of studies to determine if BITC is a possible therapy option for 
HNSCC.  Prior to presenting our findings on BITC treatment in HNSCC we will discuss why the 
need for new and alternative therapies for HNSCC is so important.   
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Chapter 2 : Head and Neck Squamous Cell Carcinoma 
 
Epidemiology and Characterization 
In the United States, head and neck cancer accounts for 3% of all malignancies and there 
are approximately 55,000 new cases each year and 12,000 related deaths [64].  Worldwide, head 
and neck cancer represents the sixth most common form of cancer, with over half a million new 
cases identified each year [65].  Two-thirds of head and neck cancer cases occur in industrialized 
nations and a predominant amount of patients are males in their 6th and 7th decade of life [66].  
Head and neck cancer encompasses every type of tissue in the head and neck region, 
including the oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx [66].  Head and 
neck squamous cell carcinoma (HNSCC) is the most prevalent form of head and neck cancer, 
and accounts for over 90% of all head and neck cancer cases [66].  HNSCC often develops from 
easily treatable dysplastic lesions; however most cases are not identified at this stage.  More than 
60% of HNSCC cases have with loco-regional (stage III) or distant metastasis (stage IV) at the 
time of diagnosis [67].  The five-year survival rate for localized HNSCC (stage I) and locally 
advanced with minimal lymph node involvement (stage II) is 80-90% [67].  However, the five-
year survival rate is 20-50% for stage III and 10-30% for Stage IV [67].  
A large portion of HNSCC cases are identified at stage III and IV, and not earlier stages 
due to the nature of the symptoms correlated with this type of cancer.  The symptoms of HNSCC 
are often non-specific and can be attributed to other health conditions.  For example, sore throat, 
nasal congestion, and hoarseness are common HNSCC symptoms and are often mistaken as the 
common cold, delaying proper diagnosis.  
Major risk factors for developing HNSCC are tobacco use, alcohol consumption, and 
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infection with certain types of human papillomavirus (HPV) [66,68,69].  Additional risk factors 
include UV radiation, exposure to certain environmental toxins, and additional strains of viruses 
outside of the HPV spectrum, such as Epstein-Barr virus [66].  Certain risk factors are localized 
to specific regions.  For example, in India there are a large number of people who use betel quids 
containing the aracea nut and this accounts for 50% of male HNSCC cases and 90% of female 
HNSCC cases [70].  However, the biggest universal risk factor for developing HNSCC is 
combining alcohol consumption with tobacco use, and this combination has been found to have a 
synergistic effect in inducing HNSCC [68].  
Reports suggest that avoiding exposure to tobacco and alcohol products could reduce 
HNSCC by 90% [66].  A decrease in incidence of HNSCC in certain areas of the world is 
attributed to programs that educate the general public about the link between smoking, alcohol, 
and HNSCC.  However, an increase in HPV infections in the Western world is diminishing the 
progress of reducing HNSCC [71].  While most cases of HNSCC are caused by tobacco and 
alcohol use, HPV-related head and neck cancers are on the rise [71].  HPV associated HNSCC 
account for a large portion of oropharynx cancers (cancer in the tonsils or the back of the tongue) 
[72].  In fact, it is reported that up to 80% of oropharyngeal cancers in the United States are due 
to infection with the HPV virus [71,73].   
The identification of HPV as a risk factor for HNSCC is relatively new, and the presence 
of the HPV virus significantly alters a patient’s treatment plan [71].  Research indicates that 
tumors initiated by HPV respond differently to treatments than tumors initiated by other causes, 
mainly because the genetic mutations and cellular pathways manipulated by HPV are different 
from the ones affected by other carcinogens [73]. 
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Classification and Staging 
 There are eight types of HNSCC identified: conventional, verrucous, basaloid, papillary, 
spindle cell (sarcomatoid), acantholytic, adenosquamous, and cuniculatum [74].  Each of these 
variants can develop in any of the head and neck regions (oral cavity, nasopharynx, oropharynx, 
hypopharynx, and larynx), except for cuniculatum (which is only identified in oral mucosa) [74].  
HNSCC can be well-, moderately-, or poorly-differentiated and the histological grades used to 
classify HNSCC are found in Table 2.1.  Most HNSCC cases are moderately to poorly-
differentiated [74].   
 
Table 2.1 Histological Grade used for HNSCC tumors.* 
Histological Grade 
GX Grade cannot be assessed 
G1 Well differentiated 
G2 Moderately Differentiated 
G3 Poorly Differentiated 
G4 Undifferentiated 
*Information adapted from the National Cancer Institute (2014) 
 
HNSCC may develop from precursor lesions (dysplasia), and in oral cancer these 
precursor lesions are called leukoplakia.  Areas of keratosis in the oral cavity are typically white 
and can be classified into different grades (Figure 2.1).  If untreated these pre-neoplastic lesions 
develop into squamocellular carcinoma (Figure 2.2).   
HNSCC is also separated into different stages of diseases.  The most common staging 
system used to grade head and neck cancers is the tumor node metastasis (TNM) classification 
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system.  The TNM classification system is a cancer staging system that helps describe the extent 
and severity of a patient’s cancer [75].  General TNM staging for head and neck cancer is 
described in Table 2.2 and is further broken down in Table 2.3.  In regards to HNSCC, T 
classifications are site specific and indicate the extent of the primary tumor, however there is 
overlap between the various head and neck regions when considering cervical node (N) 
classification [66].   
 
  
.   
 
Figure 2.1 Preneoplastic lesions in the oral cavity. 
The images depict four different stages of leukoplakia.  Images are 
from the personal collection of P.P Claudio, M.D., Ph.D.  
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Figure 2.2 Presentation of preneoplastic 
lesions that have transformed into 
squamocellular carcinoma. 
(A) Ulcerative carcinoma  (B) Exophytic 
carcinoma.  (C) Verrucous carcinoma.  Images 
are from the personal collection of P.P 
Claudio, M.D., Ph.D. 
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Table 2.1 TNM Classification used in HNSCC. * 
TNM Classification  
T Describes the size of the primary tumor and 
the extent to which it has invaded nearby 
tissue 
N Describes whether regional lymph nodes are 
involved 
M Describes if the cancer has spread from one 
part of the body to another  
*Information adapted from the National Cancer Institute (2014) 
Table 2.2 General TNM staging of HNSCC. * 
TNM Staging System 
 Staging Description 
Primary Tumor (T) TX Primary tumor cannot be evaluated 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1-T4 Size and/or extent of the primary tumor 
Regional Lymph Nodes (N) NX Regional lymph nodes cannot be evaluated 
N0 No regional lymph node involvement  
N1-N3 Degree of regional lymph node involvement 
Distant Metastasis (M) MX Distant metastasis cannot be evaluated  
M0 No distant metastasis 
M1 Distant metastasis is present 
*Information adapted from the National Cancer Institute (2014) 
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Diagnosis and Treatment  
Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission 
tomography (PET) are techniques used, in addition to a physical exam, to diagnosis HNSCC 
[74].  If a mass is identified, a biopsy or fine needle aspiration are performed to evaluate whether 
the tumor is benign or malignant.  These examination techniques are effective in identifying 
HNSCC, but unfortunately the initial symptoms of HNSCC are ambiguous and often overlooked 
[66].  Therefore, the first indication that a patient has head and neck cancer is usually after it has 
undergone metastasis to a local or regional lymph node [66].  Metastasis significantly impacts 
treatment and survival for HNSCC patients, and the most common metastatic sites are the lungs, 
bone, and liver.  Pulmonary metastasis accounts for 60% of distant metastasis, while bone and 
liver metastasis account for 22% and 10% of distant metastasis, respectively [76].  HNSCC is 
also associated with second primary malignancies, which commonly occur in other areas of head 
and neck, as well as lung and esophagus [77].  
After diagnosis, HNSCC treatment plans depend on the patient’s age, location of the 
tumor, stage of the cancer, and general health of the patient [66,76].  A large portion of patients 
presenting with stage I or stage II HNSCC will be disease free after a single modality treatment 
[76].  However, a majority of patients present with advanced HNSCC and require multi-modality 
therapy to treat their disease [74,76].  Multi-modality therapy combines surgery, radiation, and/or 
chemotherapy, and a description of each of these treatments is available in Table 2.3.  Multi-
modality therapy is currently the best treatment approach for advanced disease due to the delicate 
nature of the head and neck region.  This treatment approach helps minimize the concentration 
and dosage of any one therapy and also allows clinicians to preserve some function of affected 
tissue after surgery [76].  Minimizing dosage and exposure to anti-cancer therapy is important 
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because the oral cavity is highly susceptible to direct and indirect effects of chemotherapy and 
ionizing radiation.  
An additional factor that has a significant impact on a patient’s treatment is whether they 
test positive for HPV.  Patients with HPV-positive oropharyngeal cancers are treated differently 
from their HPV negative counterparts [72].  Additionally, HPV-positive patients have a better 
prognosis and respond to less intense therapy, compared to HPV-negative patients.  The current 
standard of treatment for HPV-positive tumors is cetuximab combined with radiation therapy.  
Cetuximab is a monoclonal antibody (MAb) that represents an example of targeted 
therapy.  Cetuximab inhibits the Epidermal Growth Factor Receptor (EGFR), which is often 
overexpressed in HNSCC.  The goal of most targeted therapy is to identify biomarkers specific 
to HNSCC, and use this knowledge to create personalized therapies [78].  This new area of 
HNSCC research designs treatments that are to stimulate the immune system or control growth 
of cancer.  In addition to the previously mentioned Cetuximab, targeted molecular therapies 
include other MAb, vaccines, and viruses, , [78,79].  These therapies are suggested to promote a 
more favorable outcome with less systemic side effects. 
The poor outcome for advanced HNSCC opens the door for other alternative therapies.  
Nutritional compounds are new methods being explored in HNSCC therapy.  These alternative 
interventions can be systemically or locally applied and can be used as adjuvants to traditional 
therapy.  BITC is one form of adjuvant therapy being investigated for HNSCC and the effects of 
this compound on HNSCC will be highlighted in Chapter 3 and 4. 
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Table 2.3 HNSCC treatment options.* 
HNSCC Treatment Options 
Therapy type Description of therapy 
Surgery Allows for removal of primary tumor and some metastatic regions. 
Techniques include surgical resection and flap reconstruction. 
Common therapy at all stages. 
 
Radiation therapy Uses high-energy x-rays or others type of radiation sources to 
prevent cancer cells from growing.  External and internal radiation 
is both used to treat HNSCC.  External radiation uses a machine 
outside of the body to send radiation to tumor.  Internal radiation 
uses radioactive substances sealed in needles, seeds, wires, or 
catheters that are placed directly into or near the cancer.  Use of 
radiation depends on stage and grade of tumor. 
 
Chemotherapy Anti-cancer agents administered systemically or regionally to stop 
the growth of cancer cells, by killing them or preventing them 
from dividing.  According to the National Cancer Institute (2014) 
there are seven chemo drugs approved by the FDA to treat head 
and neck cancer: Cisplatin, Carboplatin, Methotrexate, 
Fluorouracil, Bleomycin, Cetuximab, and Docetaxel.  Use of 
chemotherapy depends on stage and grade of tumor. 
 
*Information obtained from Up-to-Date (2014) 
  
 29 
Pitfalls of Current Treatments 
The most notable pitfall associated with HNSCC treatment is that the overall survival of 
patients has not improved over the last three decades.  Currently, the National Cancer Institute 
(2014) suggests that the overall five-year survival rate for HNSCC is 40-50%, and this 
percentage is significantly lower if a patient develops metastasis or secondary tumor in the head 
and neck region.  Around 60% of patients are diagnosed with locoregionally-advanced disease, 
and treatment of advanced HNSCC is aggressive, with significant acute and long-term effects 
[64].  Even with aggressive multi-modality therapy the five-year survival rate of locally 
advanced disease is only 30% [67].  Furthermore, the “standard of care chemotherapy” for 
advanced HNSCC disease only increases the five-year survival by 5% according to the Meta-
Analysis for Chemotherapy of Head and Neck Cancer collaborative group [67].   
On occasion, for loco-regionally advanced disease, a composite resection may be 
indicated for patients with primary tumors that entail extensive soft tissue disease around the 
mandible, thus requiring the need to sacrifice an intervening segment of mandible to accomplish 
an in-continuity resection of the primary tumor in conjunction with neck dissection.  These 
particular operations are called “commando operation” or a composite resection that entail 
excision of the intraoral primary tumor along with a segment of the intervening mandible 
performed in conjunction with ipsilateral neck dissection as a monobloc surgical resection 
(Figure 2.3).  
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Figure 2.3 Presentation of locally advanced squamous cell carcinoma. 
(A) Locally advanced oral pavement squamous cell carcinoma infiltrating the 
gingiva and the mandibular symphysis.  (B and C) Patient undergoing a 
“commando operation” in conjunction with a bilateral neck dissection.  D) Post 
operative specimen: oral pavement squamous cell carcinoma along with part of the 
tongue, a segment of the intervening mandible, and the bilateral neck lymph nodal 
dissection.  Images are from the personal collection of P.P Claudio, M.D., Ph.D.  
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The aggressive nature of HNSCC and its delicate location makes it difficult to treat with 
a single modality therapy.  A multi-modality approach is associated with the highest success rate 
for HNSCC, but often results in dramatic morphologic changes and increases in the 
inflammatory response [78].  The inflammatory changes can increase edema and fibrosis, which 
have significant impacts on a patient’s health.  Complications with eating, speaking, and 
breathing are additional effects commonly associated with both therapy and disease [78]. 
Chemotherapy and ionizing radiation also have a significant impact on the oral tissue and 
the gastrointestinal tract.  The cell turnover in the oral mucosa and the lining of the 
gastrointestinal tract is rapid and leaves these areas very vulnerable to toxicity.  The most 
common oral complications related to cancer therapies are mucositis, infection, salivary gland 
dysfunction, taste dysfunction, pain, and bleeding.  Secondary complications can arise due to 
these side-effects and lead to dehydration, dysgeusia, and malnutrition [67].   The primary and 
secondary side-effects of treatment can inhibit optimal cancer therapy because a dose reduction 
and/or modification of the treatment schedule are needed. 
Lastly, reoccurrence after treatment of HNSCC is high.  If reoccurrence or distant 
metastasis occurs patients have a poor prognosis with a median survival rate of 6-10 months 
[80].  Recurrent tumors are also resistant or unresponsive to many of the initial therapies used 
treat HNSCC. 
In conclusion, current therapy for stage I and stage II HNSCC is associated with high 
survival.  However, patients with stage III and stage IV are provided a poor prognosis, and the 
therapy available has significant impacts on quality of life.  Development of new therapies is 
needed to increase survival and improve health of patients with HNSCC.  Investigation of 
 32 
alternative treatment approaches, such as the administration of ITCs, could enhance the treatment 
of HNSCC without the detrimental side effects. 
 
Molecular Mechanisms of HNSCC 
 This section will highlight the most frequently altered molecular pathways in HNSCC.  
Understanding the molecular and genetic alterations associated with HNSCC development will 
help uncover mechanisms involved in tumor formation and identify potential targets for 
improved therapy.  Molecular techniques have already identified several tumor suppressor genes 
and proto-oncogenes linked to HNSCC development.  Loss of heterozygosity (LOH) studies 
indicate that the earliest altercations appear in 3p (p16), 9p21 (CDKN2A1), and 17p13 (TP53).  
At later stages in tumor formation, deletions of 4q, 6p, 13q and 14q and amplication of 7p and 
11q are reported [80,81].   
Early events in HNSCC carcinogenesis are linked to inactivation of p16.  Inactivation of 
p16 can be caused by LOH of 3p, homozygous deletion, point mutations, or promoter 
hypermethylation [81].  Loss of the p16 gene results in deregulation of both the p53 and pRB, 
and ultimately leads to uncontrolled proliferation [82].  Interestingly, instead of a p16 loss, HPV 
positive tumors have an overexpression of p16 in the nucleus and cytoplasm [80].  Therefore, 
p16 positivity is a reliable method for identifying HPV-positive tumors. 
Around 70-80% of HNSCC cases have a loss of 9p21 (CDKN2A1) [81].  CDKN2A1 is a 
growth suppressor and novel cell cycle regulator.  CDKN2A1 promotes cell cycle arrest by 
regulating the S phase of the cell cycle.  TGFβ1 transcriptionally-induces CDK2AP1 expression, 
and this in turn mediates the growth inhibitory activity of TGFβ1 by interacting with Cdk2 and 
inhibiting pRb phosphorylation [80]. 
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Approximately 60% of HNSCC’s harbor a TP53 mutation [81].  p53 is described as the 
“guardian of the genome” and is an important regulator of the cell cycle.  Studies report that 
alterations in p53 occur at a higher frequency in invasive carcinomas, compared to noninvasive 
carcinomas [82].   
EGFR is overexpressed in most HNSCC cases [81].  EGFR activation regulates multiple 
pathways including: MAPK, Akt, ERK and the Jak/STAT pathway [81,83].  These pathways 
regulate cellular proliferation, apoptosis, and metastasis.  Dysfunction of EGFR and its 
associated pathways occur in 80-90% of HNSCC cases [83].   
 
Models used to study HNSCC 
Cell Culture 
HNSCC is a unique cancer because it includes a variety of different regions within the 
head and neck area.  The diversity in tumor location can make designing in vitro models 
complicated, but many types of HNSCC develop from similar gene mutations.  A more 
confounding factor than tumor location when selecting a cell culture model is the presence or 
absence of HPV, because HPV-positive cell lines respond differently to treatment compared to 
HPV-negative cell lines.  HPV-negative tumors still account for around ~80% of all HNSCC 
cases.  Therefore, in our studies we chose to focus on HPV-negative cell lines that represent the 
oropharangeal region.  A model using the HN30 and HN12 cell lines was developed by George 
Yoo et al. (2000) [84].  This model was based on the observation that a p16 mutation is an early 
mutation in HNSCC development (HN30) and a p53 mutation occurs at a greater frequency at 
later stages and in invasive carcinomas (HN12) [84].  The cell lines used for in our studies are 
described in Table 2.4. 
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We also selected HN30, HN8, and HN12 because these cell lines represents three grades 
of migration potential.  The HN30 cell line does not migrate, while HN8 and HN12 cell lines 
represent moderate and high migration, respectively.  Selecting HN12 and HN8 cell lines for cell 
culture experiments have additional benefits that could be utilized in the future studies.  HN12 
and HN8 are synchronous lymph node metastases and primary tumor cell lines are available 
from the same patient.  
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Table 2.4 Characterization of HAK, HN12, HN30 and HN8 cell lines. 
*All cell lines are HPV negative;  aWT=wild-type; bMut=mutated; cdel=deleted 
 
 
Animal Models  
There are several animal models used to study HNSCC.  Models that use chemical 
carcinogens to induce tumor formation are ideal in HNSCC prevention studies.  The most 
frequently used inducers are 9,10-dimethyl-1,2-benzanthracene (DMBA) and 4-nitroquinoline-1-
oxide (4NQO) [81].  The carcinogen 4NQO can be administered through drinking water or via 
local application.  Application of 4NQO replicates the human disease from preneoplasitc lesion 
to tumor.  Additionally, this model activates oncogenes, including H-Ras (an EGFR), and is 
associated with spontaneous mutations in the tumor suppressor, p53, both of which are 
associated with HNSCC development [81]. 
No one particular xenograft model mimics HNSCC progression as is it observed in 
humans.  Currently, the best animal model to mimic human disease progression is an orthotropic 
HNSCC model [85].  This model requires injection of exponentially growing HNSCC cells into 
the tongue of athymic nude mice.  This model is associated with lymph node and regional 
Cell Line* 
 
Origin/Type p53 p16 Tumorigenic NFκB Vimentin Migration 
Capabilities 
HAK Normal Adult 
Keratinocytes 
 
WTa WT No Normal - None 
HN30 Pharynx WT Delc Yes Constitutively 
active 
+; only 
when 
grown in 
matrigel 
 
Low 
HN12 Lymph node 
metastasis 
from the 
tongue 
 
Mutb Delc Yes Constitutively 
active 
+ High 
HN8 Lymph node 
metastasis 
from primary 
oral tumor 
 
Mutb - Yes Constitutively 
active 
Unknown Moderate 
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metastasis to the lung, however the percentage of mice that present with these forms of 
metastasis is inconsistent [85].  Plus, identifying lymph node metastasis is difficult.  
Furthermore, the time it takes to grow the tumors in the tongue is longer than most xenograft 
models.  Also, these mice are reported to have problems eating and lose weight making feeding 
studies difficult.  
In another model of HNSCC, exponentially growing HNSCC cells are being 
subcutaneously injected into the hindlimb of athymic mice [85].  It is easier to measure tumor 
formation with this model, than with the orthotropic model.  This model is also acceptable for 
feeding or intravenous treatments. However, this model is not ideal to study metastasis.  
Advancements are being made in techniques to monitor metastasis and this will greatly 
improve HNSCC animal models. 
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Chapter 3 : Benzyl Isothiocyanate Inhibits HNSCC Cell Migration 
and Invasion, and Sensitizes HNSCC Cells to Cisplatin. 
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ABSTRACT 
 
Metastasis and chemoresistance represent two detrimental events that greatly hinder the 
outcome for those suffering with head and neck squamous cell carcinoma (HNSCC).  Herein, we 
investigated benzyl isothiocyanate’s (BITC) ability to inhibit HNSCC migration and invasion 
and enhance chemotherapy.  Our data suggests that treatment with BITC: 1) induced significant 
reductions in the viability of multiple HNSCC cell lines tested (HN12, HN8, and HN30) after 24 
and 48 hours, 2) decreased migration and invasion of the HN12 cells in a dose dependent 
manner, and 3) inhibited expression and altered localization of the epithelial-mesenchymal 
transition (EMT) marker, vimentin.  We also observed that a pretreatment of BITC followed by 
treatment of cisplatin: 1) induced a greater decrease in HN12, HN30, and HN8 cell viability and 
proliferation compared to either treatment alone, and 2) significantly increased apoptosis when 
compared to either treatment alone.  Taken together these data suggest that BITC has the 
capacity to inhibit processes involved in metastasis and enhance the effectiveness of 
chemotherapy. Consequently, the results indicate that further investigation, including in vivo 
studies, are warranted. 
 
Keywords: Head and Neck Squamous Cell Carcinoma, isothiocyanate, BITC, migration, 
invasion, EMT, vimentin 
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INTRODUCTION 
 
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common form of 
cancer worldwide, and the 8th leading cause of cancer-related deaths [86].  Current treatment for 
HNSCC often entails a disfiguring and risky surgical operation, combined with chemotherapy 
and/or radiation therapy [87-89].  These treatment options are associated with numerous side 
effects that dramatically affect a patient’s quality of life, and despite the aggressive treatment 
options the increase in overall survival of HNSCC has not improved in the past three decades 
[86,89-92].  The low survival rate is due, in part, to both loco-regional and distant metastasis, 
which occurs in 40-60 percent of HNSCC patients [89,92,93].  Additionally, the rate of HNSCC 
metastasis after recurrence is high, and relapse/recurrence is associated with heightened 
chemoresistance [92]. 
 A common chemotherapeutic drug used for HNSCC is cisplatin, but the side effects 
associated with effective treatment doses can be severe.  Additionally, one of the major obstacles 
in the therapeutic use of cisplatin is intrinsic or acquired resistance.  Therefore, adjuvants 
therapies that enhance the efficacy of cisplatin and/or decrease the amount of cisplatin needed to 
achieve tumor response could improve patient outcome.   
The acquisition of chemoresistance and the initiation of metastasis are complex multi-
step processes. The use of natural products, such as isothiocyanates (ITCs), which are known to 
target many cellular pathways linked to both of these processes, provides a unique therapy option 
for HNSCC.  ITCs are phytochemicals produced by several plant species, particularly 
cruciferous vegetables [6,49].  ITCs are a product of glucosinolate hydrolysis, which is initiated 
by an enzyme called myrosinase [2].  This enzyme is found spatially separated from 
glucosinolates in cruciferous vegetables and in our own human enteric microflora [2].  The 
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reactive group of ITCs, R-N=C=S, plays a significant role in ITCs involvement in numerous 
cellular pathways [4].  This functional group is known to target cysteine residues, which are 
often found in the catalytic site of many enzymes, and thereby can induce a wide range of effects 
inside a cell [7,8]. 
Benzyl isothiocyanate (BITC) is an ITC of particular interest in cancer therapy because 
of its ability to inhibit cell growth and induce apoptosis in several types of cancer cell lines, 
including HNSCC [2,25,94].  In addition to inhibiting cell growth and inducing apoptosis, BITC 
may play a role in inhibiting angiogenesis, epithelial-mesenchymal transition (EMT), and 
metastasis [13,40,95]. 
The present study builds on recent findings, which indicate that BITC may be able to 
inhibit metastasis and increase chemosensitivity.  The evidence suggests that ITCs may prevent 
migration and invasion of several types of cancer cells, but the role of BITC in prevention of 
HNSCC migration and invasion has not been investigated. We elected to focus on BITC over 
other ITCs because our preliminary screenings suggested that the concentrations needed to elicit 
a response in HNSCC appear to be lower than other ITCs studied.  Through the use of various in 
vitro studies we are reporting for the first time that BITC can inhibit migration and invasion of 
HNSCC cell lines.  The potential use of BITC as an adjuvant treatment to inhibit metastasis, 
decrease markers associated with EMT, and enhance chemotherapy is a novel treatment 
approach.  
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MATERIALS AND METHODS 
 
Materials 
Benzyl isothiocyanate (99.5% pure) was purchased from LKT Laboratories, Inc. (St. 
Paul, MN).  Stock solutions of BITC (100mM) were prepared in DMSO and diluted into growth 
medium such that the final concentration of DMSO did not exceed 0.02% (vol./vol.), a 
concentration that did not induce toxicity in HN12, HN30, HN8, and HAK cells.  Cis-
Diammineplatinum (II) dichloride (CDDP) was purchased from Sigma-Aldrich (St. Louis, MO).  
Stock concentrations of CDDP (1mg/1mL) were prepared in a 0.9% sterile saline solution.   
 
Cell Culture and Reagents 
The highly metastatic HNSCC cell line, HN12, and moderately metastatic HNSCC cell 
line, HN30, were a kind gift from Dr. George Yoo (Karmanos Cancer Center, Wayne State 
University, OH) [91].  The HN8 cell line was a gift from Dr. J. Silvio Gutkind (NIH, Bethesda, 
MD) [96].  The normal human adult keratinocyte cell line, HAK, was obtained from Zen-Bio, 
Inc. (Research Triangle Park, NC).  Monolayer cultures of HN12, HN30 and HN8 were 
maintained in DMEM (HyClone, Thermo-Scientific) adjusted to contain 10% fetal bovine serum 
(FBS) (PAA Laboratories GmbH, Pasching, Austria) and supplemented with 1% (vol./vol.) 
penicillin-streptomycin (P/S) (Corning Cellgro, Manassas, VA). HAK cells were maintained in 
Adult Keratinocyte Growth Medium (KM-2) (Zen-Bio, Research Triangle Park, NC).  Cells 
were grown in a humidified incubator at 37oC and with 5% CO2.   
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MTT Cell Viability Assay 
HN12, HN8, and HN30 cells were seeded at an initial density of 5x103 cells/well and 
HAK cells were seeded at an initial density of 15x103 cells/well in 96-well tissue culture plates 
(Corning, Corning, NY) and allowed to settle overnight.  The seeding density was selected so 
that all cell lines had a similar confluence after 24 hours.  Cells were subsequently treated with 
1.25-10M BITC for 1-hour.  After 1-hour plates were washed and media was replaced with 
fresh DMEM. The cell viability was determined after 24- and 48-hours using thiazolyl blue 
tetrazolium bromide (Sigma-Aldrich, St. Louis, MO).  Cells were incubated with dye for 2 hours, 
and then media was removed and replaced with DMSO.   Color development in the plates was 
read at 590nm using the SpectraMax M2e plate reader (Molecular Devices, Sunnyvale, CA).  The 
intensity of the color is correlated with the metabolic activity of living cells. 
 
Wound Healing Assay 
Cell migration was determined using wound healing assay.  HN12 cells were cultured in 
DMEM (10% FBS, 1% Pen-Strep) in 6-well plates until 90% confluent, and then media was 
changed to DMEM with 0.05% FBS, 1% P/S overnight to synchronize the cells.  A permanent 
line was drawn horizontally on the bottom of each well, and a plastic pipette tip was used to 
generate 3 vertical scratches per well.  Cell debris was washed away with PBS and initial scratch 
sizes were determined with an inverted light microscope (Olympus IX51, Center Valley, PA) at 
100X magnification.  Six measurements were made per well, 1 below and 1 above the horizontal 
line for each scratch before treatment.  Cells were treated with 2.5-5M BITC for 1-hour at 
37oC.  DMSO, at the same concentration as in the BITC treated wells, was used for the vehicle 
control.  After 1-hour plates were washed with PBS and treatment was replaced with DMEM 
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(10% FBS, 1% P/S).  Wound healing was analyzed 24 hours after treatment.  Images were taken 
at 100X magnification, as described above, and changes in cell migration were determined by 
calculating the percent of wound healing.  Percent wound healing= ([scatcht-0hr - scatcht-
24hr]/scatcht-0hr)*100.  Experiments were repeated 3 times. 
 
Invasion Assay 
The effect of BITC on invasion of HN12 cells was determined using Invasion Chambers 
with 8μm pores (BD Biocoat, Franklin Lakes, NJ).  Polycarbonate membranes on the bottom of 
the Boyden chamber inserts were rehydrated following manufacturer’s instructions and 0.5mL of 
HNSCC cell suspension containing 5x104 cells was added to each insert.  Cells were allowed to 
attach for 4 hours prior to treatment in complete DMEM media (10% FBS, 1%P/S).  After 
attachment the appropriate wells were treated for 1-hour with BITC (2.5-5μM) in serum free 
DMEM.  Epidermal growth factor (EGF) was used at (10ng/1mL in serum free DMEM (0.5% 
BSA, 1% P/S)) was added to the bottom well in all wells, except for the negative control, as a 
chemoattractant.  Media in all inserts was replaced after 1-hour with DMEM (0.5% BSA, 1% 
P/S).  Analysis of cell invasion was performed 24 hours after beginning treatment.  Media and 
cells were removed from the top of the matrigel following manufactures’ instructions and cells 
were fixed with 100% methanol, washed with PBS, and stained with 0.1% Crystal Violet.   Cells 
counts were performed and images taken using an Olympus IX51 inverted light microscope 
(Olympus, Center Valley, PA) at 400X magnification.  Twenty fields of view were counted for 
each sample and averaged to determine the mean number of cells/field of view.  Experiments 
were repeated a minimum of 3 times. 
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Western Blot Analysis 
Vimentin and bcl-2 expression were analyzed 24 hours after BITC treatment in HNSCC 
cells.  Cell pellets were lysed with RIPA buffer (1% NP-40, 0.1% SDS, 50mM Tris-HCl pH 7.4, 
150mM NaCl, 0.5% Sodium Deoxycholate, 1mM EDTA) for analysis.  Densitometry was 
calculated using α-actin (SantaCruz, Santa Crutz, CA) as a loading control for all Western blots. 
Vimentin antibody (AVIVA, San Diego, CA) was used at a 1:1000 dilution in a 5% 
milk/TBST buffer.  Horseradish peroxidase-conjugated goat anti-rabbit secondary antibody 
(Rockland, Gilbertsville, PA) was used (1:10,000).  The signal was developed with ECL Prime 
western blotting detection reagent (Amersham, Piscataway, NJ).   
Bcl-2 antibody (SantaCruz, Santa Crutz, CA) was used at a 1:1000 dilution in a 5% 
milk/TBST buffer.  Horseradish peroxidase-conjugated goat anti-mouse secondary antibody 
(Rockland, Gilbertsville, PA) was used (1:5,000).  The signal was developed with ECL Prime 
Western blotting detection reagent (Amersham, Piscataway, NJ).  
 
Indirect Immunofluorescence 
HN12 cells were seeded initially at a density of 4x104 in Nunc Lab Tek II 
immunofluorescence chambers (Fisher Scientifics, Pittsburgh, PA).  Cells were allowed to attach 
overnight before treatment with BITC (5-10μM) for 1-hour.   Treatment media was then 
removed and replaced with complete DMEM (10%FBS, 1%P/S).  Twenty-four hours after 
treatment, cells were fixed with 4% paraformaldehyde and permeabilized in PBS containing 1% 
BSA and 0.1% Triton X-100.  Cells were blocked with PBS/1% BSA prior to staining.  Vimentin 
(AVIVA, San Diego, CA) was diluted 1:400 with PBS containing 1% BSA and appropriate wells 
were incubated with primary antibody in a dark humidified chamber for 1-hour.  Cells were then 
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washed and incubated with Alexa Fluor 488 (Invitrogen, Grand Island, NY) secondary antibody 
(1:200) in humid and dark conditions for 45 minutes.  Slides were detached from 
immunofluorescence chambers and Vectashield mounting media with DAPI (Vector 
Laboratories, Burlingame, CA) was added to slides before analysis.  Images taken using an 
Olympus IX51 inverted microscope equipped with epifluorescence (Olympus, Center Valley, 
PA). 
 
MTT Cell Viability/Chemosensitivity Assay 
HN12, HN8, and HN30 cells were seeded at an initial density of 5x103 cells/well in 
Corning 96-well tissue culture plates (Corning, NY) and allowed to settle overnight.  Cells were 
then treated with 2.5-10M BITC for 1-hour, 5-10M of CDDP for 24 hours, or a 1-hour 
pretreatment of 2.5-10M BITC followed by a treatment of 5-10M of CDDP for 24 hours.  
Media was changed in all wells 24 hours after cisplatin treatment prior to the 48-hour analysis.  
Cell viability was determined 24 or 48 hours later as described above under MTT Cell 
Proliferation/Viability Assay methods.  Results were performed in technical quadruplets with 
three biological replicates. 
 
Trypan Blue Dead/Live Assay 
HN12, HN8, and HN30 cells were seeded at an initial density of 3x105 cells/well in 
Corning 6-well tissue culture plates (Corning, NY) and allowed to settle overnight.  Cells were 
then treated with 5-10M BITC for 1-hour, or 10M of CDDP for 24 hours, or a 1-hour 
pretreatment with 5-10M BITC followed by 10M of CDDP for 24 hours.  Cell counts were 
performed 24 and 48 hours after initiating CDDP treatment.  Cells were trypsinized and washed 
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in PBS prior to cell count.  Cells in each treatment group were mixed 1:1 with a trypan blue 
solution (0.4% trypan blue in PBS) and counted using a hemacytometer. 
 
Annexin-V/PI Assay 
HN12 and HN30 cells were seeded at an initial density of 2x106 cells in 10cm Corning 
tissue culture dish (Corning, NY) and allowed to settle overnight.  Cells were treated as 
described above in the Dead/Live assay methods.  Treatment-induced cell death was determined 
by flow cytometry using an Annexin-V assay kit (eBiosciences, San Diego, CA).  24 and 48 
hours after initiating CDDP treatment cells were collected and 1x106 cells per group were 
subjected to a double staining with an Annexin-V-FITC antibody and Propidium Iodide 
following the manufacturer’s instructions.  Cells were analyzed using an Accuri C6 Flow 
Cytometer (BD Accuri, San Jose, CA).  Early apoptosis was defined as cells positive for 
Annexin-V-FITC only.  Late apoptosis was defined as cells positive for Annexin-V-FITC and 
Propidium Iodide (PI). Necrosis was defined as cells positive for PI only 
 
Statistical Analysis 
All experiments were performed at least three times as independent experiments.  
Statistical analyses were done with a multiple comparison test with appropriate post-hoc test.   
GraphPad Prism (La Jolla, CA) was used for all statistical analysis. A p-value of <0.05 was 
considered statistically significant.   
The combination index of BITC and cisplatin combination was analyzed using the 
following equation: CI=(CA,X/ICX,A) + (CB,X/ICX,B) as described in Zhao et al. (2010) [97].  In 
this equation CI is the combination index; CA,X  and CB,X are the concentration of drugs A and B 
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used in a combination that generates x% of the maximal combination effect;  ICx is the drug 
concentration needed to produce x% of the maximal effect.  A CI of less than, equal to, and more 
than 1 indicates synergy, additivity, and antagonism, respectively. 
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RESULTS 
 
BITC Decreased the Cell Viability of Three HNSCC Cell Lines  
MTT assay results indicate that a 1-hour treatment of 10μM BITC significantly decreased 
the cell viability (p≤0.05) of the HN12, HN8 and HN30 cell lines after 24 and 48 hours (Fig 3.1 
A and B).  However, a 1-hour treatment of 2.5-5μM BITC did not significantly affect the cell 
viability of these HNSCC cell lines after 24 hours, and at 48 hours a significant decrease in cell 
viability was only observed in the HN30 cell line after a 5μM BITC treatment (Figure 3.1 A and 
B).  Treatment of the normal keratinocyte cell line (HAK) with 2.5-10μM BITC did not decrease 
cell viability (Figure 3.1 A and B).  Thus, BITC has selective toxicity for HNSCC cancer cells. 
A 1-hour treatment was selected for future experiments because the cell viability of HNSCC 
cells was not significantly different whether treated with 2.5-10μM BITC for 1, 16, or 24 hours 
(data not shown). 
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Figure 3.1 HNSCC percent viability measured by MTT assay following 
exposure to BITC treatments.   
(A) Percent viability of HAK, HN12, HN30 and HN8 cells at 24 hours.  (B) 
Percent viability of HAK, HN12, HN30 and HN8 cells at 48 hours.  (*)indicates 
significant difference from respective cell line vehicle control.  Percent viability 
was assessed by comparing treatment values to negative control.  Error bars 
represent standard deviation.  One-way ANOVA for multiple comparisons with 
Dunnet’s Post-Hoc test (*p≤0.05). 
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BITC Inhibited Migration and Invasion of HNSCC Cells 
A wound-healing assay indicated that BITC inhibits migration of the highly metastatic 
HN12 cells in a dose dependent manner.  After 24 hours, inhibition of cellular migration was 
observed in the highly metastatic HN12 cell line when using a 2.5µM BITC treatment, however 
a significant decrease in wound healing required 5µM BITC (p≤0.05) (Figure 3.2 A and B). 
Similar results were observed when using the HN8 cell line, but not the HN30 cell line (data not 
shown).  Although, it should be noted that the HN30 cell line did not undergo “wound-healing” 
under control conditions. 
The ability of BITC to inhibit the migration of HN12 cells prompted us to investigate the 
effect of BITC on invasion through Matrigel.  Figure 3.3 (panels A and B) depict that 1-hour 
treatment of BITC significantly inhibited the invasion of HN12 cells (p≤0.05).  Compared to the 
vehicle control the average number of invading cells per field of view decreased by 52.34% after 
a 2.5μM BITC treatment and 90.96% after a 5μM BITC treatment (p≤0.05).  Viability assays 
confirmed that the addition of the chemo-attractant, EGF, to the cells did not change the viability 
and proliferation of HNSCC cells after BITC treatment (data not shown).  These results 
substantiate the wound-healing assay data and indicate that BITC targets both migration and 
invasion of certain HNSCC cell lines.  
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Figure 3.2 BITC inhibited wound-healing of the HN12 cell line after 24 hours.   
(A) Inverted light microscope images of HN12 cells 24 hours after a 1-hour BITC treatment (2.5-
5µM).  Dashed lines represent scratch size before treatment. Vehicle control was DMSO. 
Magnification 100X.  (B) Bar diagram represents the percent wound healing determined after 24 
hours using wound size measurements.   Error bars represent standard deviation.  One-way ANOVA 
for multiple comparisons with Dunnet’s Post-Hoc test (*p≤0.05). Neg: negative control. Veh: vehicle 
control. 
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Figure 3.3 BITC treatment inhibited 
invasion of the HN12 cell line after 24 
hours.  
(A) Bar diagram represents the average 
number of invading cells/field of view 
counted at 24 hours following a 1-hour 
treatment of HN12 cells with BITC.  
EGF was used as chemoattractant.  Error 
bars represent standard deviation.  One-
way ANOVA for multiple comparisons 
with Dunnet’s Post-Hoc test (*p≤0.05).  
(B)  Inverted light microscope pictures of 
HN12 cells stained with crystal violet 
following BITC treatment.  
Magnification 200X.  .Neg: negative 
control. Veh: vehicle control.   
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Vimentin Expression Decreased after BITC Treatment  
Vimentin is an intermediate filament protein associated with EMT and HNSCC cell 
invasion [98,99].  We determined BITC treatment alters vimentin expression or localization.  We 
observed that vimentin expression was inhibited 24 hours after a 1-hour BITC treatment (2.5-
10μM), in a dose dependent manner (Figure 3.4 A).  The localization of vimentin also appeared 
altered after BITC treatment.  In the vehicle control vimentin was evenly dispersed, and was also 
observed in cellular projections.  However, after BITC treatment these projections disappeared, 
and vimentin was observed as aggregates inside the cells.  Our immunofluorescence results are 
supported by Western blot analysis showing a significant decrease in vimentin expression 
occurred after a 24 hour BITC treatment of 5 and 10μM (p≤0.05) (Figure 3.4 B and C).  
Although the treatment conditions changed for the Western blot analysis, cellular viability of 
HNSCC cells did not change whether treated with BITC for 1, 16, or 24 hours (data not shown).   
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Figure 3.4 Vimentin expression in 
the HN12 cell line decreased 
following BITC treatment. 
(A) Representative 
immunofluorescence images of a 
vimentin immunostaining in HN12 
cells acquired with an inverted 
epifluorescence microscope 24 hours 
after a 1-hour treatment with a range 
of concentrations of BITC (5-10µM).  
Anti-vimentin (1:400); AbII anti-
rabbit Alexa Fluor 488 (1:200); 
DAPI to counterstain the nuclei.  
Magnification 400X. Bar size is 
10µm.  (B) Western blot analysis of 
vimentin expression in HN12 cells 
24 hours after a 1-hour treatment 
with a range of concentrations of 
BITC (1.25-10µM).  Actin was used 
to normalize the blot.  (C) 
Densitometric analysis of vimentin 
and actin protein expression. 
Diagram represents the fold change 
of vimentin after 24 hours 
normalized to actin control.  Ctrl: 
negative control. Veh: vehicle 
control.  One-way ANOVA for 
multiple comparisons with Dunnett’s 
Post-Hoc test (*p≤0.05). 
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Pretreatment with BITC Followed by Cisplatin Decreased HNSCC Cell Viability and 
Enhanced Cell Death 
 One of the major obstacles in the therapeutic use of platinum analogues is intrinsic or 
acquired resistance [100-103].  The high cisplatin resistance observed in our HNSCC cell lines 
prompted us to investigate whether BITC treatment of HNSCC cells enhances their response to 
CDDP. 
A 1-hour pretreatment of BITC enhanced the effect of CDDP after 24 and 48 hours, 
compared to either BITC or CDDP treatment alone (p≤0.05) (Figure 3.5 A-C).  The strongest 
decrease in cell viability was observed at 48 hours when the HNSSC cells were pretreated with 
10µM BITC followed by 10µM CDDP treatment (Combination index CI= 0.52 to 0.93) 
(p≤0.0001) (Figure 3.5 A-C).  Combination of 10µM BITC and 10µM cisplatin showed a 
synergistic effect in HN8 cells at 48 hours (CI= 0.73), but only additive effect at 24 hours (CI= 
1.09).  
A synergistic effect was also observed at 24 and 48 hours in HN30 (24 hours CI= 0.79; 
48 hours CI= 0.52) and HN12 cells (24 hours CI= 0.86; 48 hours CI= 0.93) following a 
combination treatment of 10µM BITC and 10µM cisplatin (Figure 3.5).   
The MTT assay assesses changes in cell viability, however the MTT assay does not 
differentiate between proliferation and/or cell death.  Therefore, we used a trypan blue dead/live 
assay and an Annexin-V assay (apoptosis) to determine if BITC pretreatment increased cell 
death.  The trypan blue dead/live assay (Figure 3.6 A, B, D, E, G, and H) indicated that cell 
death was significantly enhanced by BITC pretreatment followed by CDPP in all three HNSCC 
cells (HN8, HN12, and HN30), compared to treatment with either compound alone.  However, 
the most dramatic increase in cell death was observed when HN30 cells were pretreated for 1-
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hour with 10µM BITC followed by a 24-hour 10µM CDDP treatment, synergistic effect CI= 0.9; 
p≤0.0001) (Figure 3.6 D). These results were verified by numerical cell counts at the 24 and 48 
hour time points of the different treatment groups (Figure 3.6 C, F, and I).   
An Annexin-V assay showed a significant increase in early and late apoptosis after a 
pretreatment of 10µM BITC followed by 10µM CDPP in both the HN30 and HN12 cell lines 
after 24 hours (p≤0.001) (Figure 3.7 A and B).  Additionally, the total percent of dead cells 
(early, late apoptosis, and necrosis) increased significantly when cells were pretreated for 1-hour 
with 10µM BITC followed by a 24-hour 10µM CDDP treatment (p≤0.0001).   
Together the results of the MTT assay, dead/live assay, cell counts, and Annexin-V assay 
show that pretreatment of HNSCC cells with BITC followed by CDDP significantly increased 
HNSCC cell death relative to either agent used as a single therapeutic. 
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Figure 3.5  Dead/Live cell viability assay and cell counts of HNSCC cells following treatment 
with BITC, CDDP, or a pretreatment of BITC followed by CDDP. 
(A-B) Diagrams represent the percent of HN12 cells that were alive after 24 (A) and 48 (B) hours 
following BITC, CDDP, or a pretreatment of BITC followed by a CDDP treatment.  (C) Diagram 
depicts cellular proliferation of HN12 cell line 24 and 48 hours after a BITC, CDDP, or a pretreatment 
of BITC followed by a CDDP treatment.  (D-E) Diagrams represent the percent of HN30 cells that 
were alive after 24 (D) and 48 (E) hours following BITC, CDDP, or pretreatment of BITC followed 
by a CDDP treatment. (F) Diagram depicts cellular proliferation of HN30 cell line 24 and 48 hours 
after a 24 and 48 hours following BITC, CDDP, or a pretreatment of BITC followed by a CDDP 
treatment.  (G-H) Diagrams represent the percent of HN8 cells that were alive after 24 (G) and 48 (H) 
hours following BITC, CDDP, or a pretreatment of BITC followed by a CDDP treatment.  (I) 
Diagram depicts cellular proliferation of HN8 cell line 24 and 48 hours after a BITC, CDDP, or a 
pretreatment of BITC followed by a CDDP treatment.  Control: negative control.  Vehicle: vehicle 
control.  Cis: Cisplatin/CDDP.  Error bars represent standard deviation.  Error bars represent standard 
deviation.  One-way ANOVA for multiple comparisons with Dunnet’s Post-Hoc test (*p≤0.05; 
**p≤0.001; ***p≤0.0001). 
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Figure 3.6 MTT viability assay of HNSCC cells following treatment with BITC, CDDP, or a 
combination of BITC followed by CDDP compared to controls. 
(A) Diagram represents the percent of HN12 viable cells after 24 and 48 hours following BITC, 
CDDP, or a pretreatment of BITC followed by a CDDP treatment (24 hours CI= 0.86; 48 hours 
CI= 0.93).  (B) Diagram represents the percent of HN30 viable cells after 24 and 48 hours 
following BITC, CDDP, or a pretreatment of BITC followed by a CDDP treatment (24 hours CI= 
0.79; 48 hours CI= 0.52).  (C) Diagram represents the percent of HN8 viable cells after 24 and 48 
hours following BITC, CDDP, or a pretreatment of BITC followed by a CDDP treatment (24 
hours CI= 1.09; 48 hours CI= 0.73).  Dark grey bars indicate cell viability at 24 hours; light grey 
bars indicate cell viability at 48 hours.  Ctrl: negative control.  Veh B+C: vehicle control.  B: 
BITC. C: Cisplatin/CDDP.  Error bars represent standard deviation.  One-way ANOVA for 
multiple comparisons with Dunnet’s Post-Hoc test (*p ≤ 0.05; **p ≤ 0.001; ***p≤0.0001). 
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Figure 3.7 Annexin-V assay of HN12 and HN30 cells following treatment with BITC, CDDP, or 
a pretreatment of BITC followed by CDDP. 
(A) Bar diagram represents the percent of HN12 cells that are in early/late apoptosis or necrosis 24 
hours after a BITC, CDDP, or a pretreatment of BITC followed by a CDDP treatment.  (B) Bar 
diagram represents the percent of HN12 cells that are in early/late apoptosis or necrosis 24 hours after 
a BITC, CDDP, or a pretreatment of BITC followed by a CDDP treatment.  Black bars represent 
necrosis, white bars early apoptosis, and grey bars late apoptosis.  Error bars represent standard error 
of the mean.  Ctrl: negative control.  Veh: vehicle control.  Cis: Cisplatin/CDDP.  One-way ANOVA 
for multiple comparisons with Dunnet’s Post-Hoc test (*p≤0.05; **p≤0.001; ***p≤0.0001). 
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BITC Treatment Deceases the Expression of Anti-apoptotic Protein Bcl-2  
Bcl-2 is an anti-apoptotic protein that is overexpressed in most cancer cells.  Western blot 
analysis indicates that a 1-hour BITC treatment reduces the expression of bcl-2 in the HN12 cell 
line after 24 hours (Figure 3.8 A and B).  A decrease in bcl-2 expression is observed after a 
5µM BITC treatment, but the reduction in bcl-2 is not statistically significantly until after a 
10µM BITC treatment (p≤0.05).  A decrease in bcl-2 expression supports the annexin-V assay, 
and indicates that BITC treatments increase apoptosis in HNSCC cell lines. 
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Figure 3.8  Bcl-2 Expression decreased in the HN12 cell line 24 hours after BITC 
treatment. 
(A) Western blot analysis of bcl-2 expression in HN12 cells after a 1-hour treatment 
with 5 or 10µM BITC.  Actin was used to normalize the blot.  (B) Densitometric 
analysis of bcl-2 and actin protein expression. Diagram represents the relative 
expression of bcl-2 after 24 hours normalized to actin control.  Neg: negative control.  
Veh B+C: vehicle control.  B: BITC.  Error bars represent standard deviation.  One-
way ANOVA for multiple comparisons with Dunnett’s Post-Hoc test (*p≤0.05). 
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DISCUSSION 
 
The treatment for HNSCC often involves a disfiguring surgical operation and either prior 
or subsequent chemotherapy and/or radiation therapy [86,104].  These combined treatment 
modalities are often associated with side effects that reduce the patient’s quality of life.   HNSCC 
metastasis and chemoresistance are two of the leading reasons for this multimodal treatment 
approach.  The inability to effectively target these events, whether separately or together, leads to 
a poor prognosis.  Consequently, those who suffer from aggressive HNSCC face a debilitating 
disease, and need improved therapeutic options. 
ITCs are natural compounds exhibiting potent anti-tumor effects in both cell culture and 
animal models [20,39,40,105].  In humans, ITCs are safe at clinically relevant concentrations and 
have high oral bioavailability, making them promising adjuvant therapy tools for the treatment of 
cancer [2,5,105].   Here, we show that BITC inhibits HNSCC cell migration and invasion, as 
well as sensitizes HNSCC cells to the chemotherapeutic drug cisplatin at clinically relevant 
concentrations [39,95].  Additionally, BITC decreased the expression of vimentin, a marker 
associated with EMT, in the HN12 cell line. 
Tumors are not homogenous and may have different aberrant pathways that contribute to 
maintenance of cancer phenotype.  The type of mutations present in different cancer cell could 
play a significant role on the different pathways and molecular targets of BITC.  Since BITC’s 
targets appear to be multifactorial we decided to focus primarily on the end points of cell death, 
proliferation, migration and invasion.  Collectively our results illustrate that the effects of BITC, 
in regards to migration/invasion and chemoenhancement (greater anti-neoplastic effect than the 
sum of BITC or CDDP treatment alone) are not cell line specific.  Importantly, BITC selectively 
targeted the viability of HNSCC cells, but not normal keratinocytes (Figure 3.1).  
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Vimentin expression in epithelial cells is a marker for epithelial-mesenchymal transition 
(EMT).  Vimentin's overexpression in HNSCC correlates well with accelerated tumor growth, 
invasion, and poor prognosis [106].  Therefore, vimentin serves as an attractive potential target 
for HNSCC therapy.  Many EMT markers are correlated with poor HNSCC prognosis, but few 
therapies have been shown to actually regulate the expression of these markers.  Additionally, 
EMT, directly or indirectly links HNSCC metastasis and chemoresistance. Our findings that 
BITC treatment decreases vimentin expression in HNSCC cells suggest these cells are less likely 
to undergo EMT following BITC exposure indicating a unique property of this phytochemical 
that could be exploited for therapy.  
Despite significant improvements in treatment modalities, long-term survival rates in 
patients with advanced-stage HNSCC have not increased significantly in the past 30 years.  
Radiation and chemotherapy are nonselective and can cause damage to normal tissue. Cisplatin 
is one example of a non-selective drug commonly used to treat HNSCC.  This drug is associated 
with many detrimental side effects.  Additionally, intrinsic or acquired resistance to platinum 
analogues is a major obstacle in HNSCC therapy.  The results of our MTT assay, dead/live 
assay, cell counts, and Annexin-V assay support the use of BITC to either counteract cisplatin 
resistance or enhance its activity (Figure 3.5 and Figure 3.6).  The concentrations selected for 
these studies mimic the peak plasma concentration of cisplatin [107,108].  
In conclusion, our results show that BITC targets cell viability and reduces the amount of 
migration and invasion of HNSCC cells, but not of normal keratinocytes.  The inhibition of 
migration and invasion we observed may be due to the ability of BITC to target key players 
involved in EMT, such as vimentin.  Additionally, pretreatment with BITC chemosensitized the 
HNSCC cells to cisplatin by decreasing cell viability and increasing cell death suggesting that 
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BITC could be a novel adjuvant therapy for patients with aggressive HNSCC.  These initial 
findings warrant future in vivo animal studies to ensure that BITC can reach tumor cells in 
adequate concentrations to induce xenograft or organotypic human HNSCC tumors to undergo 
the changes in viability and drug sensitivity that we have documented in cell culture. 
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Chapter 4 : Benzyl Isothiocyanate Induced ROS Regulates HNSCC 
Cell Migration and Viability 
 
 
ABSTRACT 
In comparison to non-malignant cells, cancerous cells tend to display elevated levels of 
basal reactive oxygen species (ROS).  As a consequence of the elevated levels of basal ROS, 
cancer cells are highly dependent on antioxidant defense systems.  Therapeutic agents that 
abrogate or compromise the antioxidant system can leave cancer cells particularly vulnerable to 
the cytotoxic effects of ROS.  Head and neck squamous carcinoma (HNSCC) cells are sensitive 
to treatments that alter the antioxidant system and induce ROS.  Isothiocyanates (ITCs) are 
known inducers of ROS.  Using a dicholorofluorescein (DCF) assay, as a measure of 
intracellular ROS, we demonstrate that the ITC, benzyl isothiocyanate (BITC), significantly 
increased ROS production in the HN12 and HN30 HNSCC cell lines.  The increase in ROS was 
attenuated by the addition of antioxidants, N-acetyl-L-cysteine (NAC) and catalase.  BITC, at 
concentrations that did not affect HNSCC cell viability, prevented wound healing in the HN12 
cell line.  The addition of either NAC or catalase reversed the wound healing inhibitory effect of 
BITC.  NAC or catalase also prevented BITC-induced cytotoxicity in the HN12 and HN30 cell 
lines.  Additionally, NAC reduced the cytotoxic effects of the combinatorial treatment of BITC 
and cisplatin.  Collectively, these results suggest that ROS are important components in BITCs 
ability to induce cytotoxicity and inhibit migration in HNSCC.  
 
Keywords: Head and Neck Squamous Cell Carcinoma, isothiocyanate, BITC, migration, 
reactive oxygen species, N-acetyl-L-cysteine, catalase  
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INTRODUCTION 
 
We have previously shown that benzyl isothiocyanate (BITC) treatment inhibits 
migration and invasion and enhances the effects of the chemotherapeutic drug, cisplatin, in 
HNSCC cell lines [44].  However, the mechanism through which BITC elicits its effects on 
HNSCC cells remains unclear.  In the present study, we investigated whether reactive oxygen 
species (ROS) induction is a possible mechanism by which BITC can prevent migration and add 
to the effectiveness of chemotherapy. 
Malignant transformation often leads to an altered antioxidant system that promotes 
cancer cell survival. Additionally, pathways effected by these alterations lead to resistance from 
anti-cancer agents [44].  Manipulating the antioxidant system by altering the levels of glutathione 
(GSH) and/or ROS can provide a biochemical basis to selectively kill cancer cells, while leaving 
normal cells unaffected.  Normal cells have low levels of basal ROS and the antioxidant system 
is able to tolerate inductions of ROS [23,98,109].  However, in cancer cells, an increase in basal 
ROS generation renders these cells highly dependent on the antioxidant system and agents that 
abrogate or compromise this system can leave the cancer cells vulnerable [109,110].  
Consequently, anti-cancer agents that manipulate the redox balance are effective in treating a 
variety of cancers, including HNSCC [23,44,45,109,111].  
Inducers of ROS are effective in triggering apoptosis in HNSCC cells thereby indicating 
that agents like isothiocyanates (ITCs), which are shown to increase oxidative stress, are ideal 
candidates for HNSCC therapy.  However, ROS are still regarded as key meditators in numerous 
cellular pathways that lead to growth and survival, warranting a proper investigation in ROS 
inducing anti-cancer agents [23].  Traditionally, the research on ROS-inducing anti-neoplastic 
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drugs focused on whether the treatment kills cancer cells, and little attention has gone in to 
understanding how ROS inducers may effect migration and invasion [23,110].  The conundrum 
of ROS therapy is that ROS inducing agents are strongly associated with increased migration and 
invasion of cancer cells [112,113].  However, a study by Luanpitpong et al. (2010) showed that 
in HN460 lung cancer cells certain ROS (OH•) increased cell migration while others (O2  and 
H2O2) decreased cell migration.  This same study indicated that catalase, which is a H2O2 
scavenger, increased migration [114].   
Results from our lab using HNSCC cells support the findings of Luanpitpong et al. 
(2010) and suggest that the type of ROS induced may be important in modulating HNSCC cell 
migration [114].  Here we show that BITC treatments significantly induced ROS and suppressed 
cell migration in HNSCC cell lines and that by modulating BITC induced ROS levels with either 
N-acetyl-L-cysteine (NAC) or catalase we restored HNSCC cell migration.  In regards to 
decreased cell viability in HNSCC cell lines, we have shown that NAC inhibited the additive 
effects of BITC pretreatment followed by cisplatin.  
In conclusion, BITC targets many molecular pathways in the cell that alter migration, 
invasion, and cell death.  Here, we demonstrate that ROS play an important role in the ability of 
BITC to alter migration and invasion and induce cell death. 
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MATERIALS AND METHODS 
 
Materials 
Benzyl isothiocyanate (99.5% pure) was purchased from LKT Laboratories, Inc. (St. 
Paul, MN).  Stock solutions of BITC (100mM) were prepared in DMSO and diluted into growth 
medium such that the final concentration of DMSO did not exceed 0.01% (vol./vol.), a 
concentration that did not induce toxicity in HN12 and HN30 cells.  2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA) was purchased from Molecular Probes (Grand 
Island, NY).  Stock solutions of H2DCFDA (50mM) were prepared in DMSO in the dark and 
diluted into serum free growth medium.  N-Acetyl-L-cysteine (NAC) and Catalase from bovine 
liver were both purchased from Sigma-Aldrich (St. Louis, MO).  Stock solutions of NAC 
(100mg/mL) were prepared in sterile Milli-Q water and diluted into serum free growth medium.  
Catalase treatments (2,500U/mL) were prepared in serum free growth medium.  Cis-
Diammineplatinum (II) dichloride (CDDP) was purchased from Sigma-Aldrich (St. Louis, MO).  
Stock concentrations of CDDP (1mg/1mL) were prepared in a 0.9% sterile saline solution.  
 
Cell Culture and Reagents 
The highly metastatic HNSCC cell line, HN12, and moderately metastatic HNSCC cell 
line, HN30, were a kind gift from Dr. George Yoo (Karmanos Cancer Center, Wayne State 
University, OH) [44,91].  Monolayer cultures of HN12 and HN30 were maintained in 
Dulbecco’s Modified Eagles Medium (DMEM) (HyClone, Thermo-Scientific) adjusted to 
contain 10% fetal bovine serum (FBS) (PAA Laboratories GmbH, Pasching, Austria) and 
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supplemented with 1% (vol./vol.) penicillin-streptomycin (P/S) (Corning Cellgro, Manassas, 
VA).  Cells were grown in a humidified incubator at 37oC and with 5% CO2.  
 
Intracellular ROS Generation 
Cells were seeded in 6-well plates (3x105 cells/well) 24 hours prior to treatment.  Levels 
of intracellular ROS were determined using 5-(and-6-) chloromethyl-2’,7’-dichlorodihydro-
fluorescein diacetate, acetyl ester (CM-H2DCFDA) (Molecular Probes, Eugene, OR).  Cells were 
washed twice with 1X Dulbecco’s PBS (PBS) (GIBCO, Invitrogen) and incubated for 5 minutes 
in the presence or absence of 2.5μM H2DCFDA in serum free DMEM.  Following a 5 minute 
incubation, cells were washed three times with 1X PBS and treated with BITC (1.25-10μM), 
5mM NAC, 2,500U catalase, or a combination of BITC and NAC or BITC and catalase for 1 
hour.  After treatment cells were washed two times with 1X PBS and then incubated with 
StemPro® Accutase® (Life Technologies, Grand Island, NY) for 5 minutes.  H2O2 (10μM) was 
used as positive control.  Cells were collected and transferred to 1.5mL microcentrifuge tubes 
and spun down at 400xg for 5 minutes.  The supernatant was removed and cells were washed 
two times with 500μL PBS.  Cells were re-suspended in 400μL of PBS and kept one ice and 
fluorescence was determined using an Accuri C6 Flow Cytometer (BD Accuri, San Jose, CA).  
Assays for intracellular ROS generation were performed in technical triplicates and biological 
triplicates. 
 
Immunofluorescence 
Cells were seeded and treated as described above in the Intracellular ROS Generation 
methods.  After treatment cells were washed two times with 1X PBS.  Wells were filled with 2 
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mL of PBS prior to microscopy.  Images were taken using an Olympus IX51 inverted 
microscope equipped with epifluorescence (Olympus, Center Valley, PA). 
 
NF-κBp50 activity assay 
NF-κBp50 activity was evaluated in HNSCC cell lines 24 hours after a 1-hour BITC 
treatment using an NF-κB p50 Transcription Factor Kit (Pierce Biotechnology, Rockford, IL), 
according to manufacturer’s protocol.  The kit contains streptavidin-coated 96-well plates and an 
NF-κB biotinylated-consensus sequence.  Only the active form of NF-κB will bind to the DNA 
consensus sequence.  A wild type NF-B competitor and a mutant NF-B competitor were used 
to ensure the signal specificity of the assay.  A TNFα activated HeLa cell nuclear extract was 
used as a positive control.  HNSCC cell pellets were lysed after treatment with RIPA buffer (1% 
NP-40, 0.1% SDS, 50mM Tris-HCl pH 7.4, 150mM NaCl, 0.5% Sodium Deoxycholate, 1mM 
EDTA).  Protein extracts containing 5µg of protein/well were added in triplicates to appropriate 
microplate wells.  Luminescence resulting from a reaction with bound NF-κB was detected using 
a SpectraMax L plate reader (Molecular Devices, Sunnyvale, CA).  
 
Co-treatment MTT Cell Viability Assay  
HN12 and HN30 cells were seeded at an initial density of 5x103 cells/well in 96-well 
tissue culture plates (Corning, Corning, NY) and allowed to settle overnight.  Cells were treated 
with BITC (2.5-10μM), 5mM NAC, 2,500U/mL catalase, and a combination of BITC and NAC 
or BITC and catalase for 1-hour.  All treatments were prepared in DMEM containing 0.05% 
FBS, 1% P/S.  After 1-hour plates were washed and media was replaced with fresh DMEM 
containing 10% FBS, 1% P/S.  The cell viability was determined after 24- and 48-hours using 
 71 
thiazolyl blue tetrazolium bromide (Sigma-Aldrich, St. Louis, MO).  Cells were incubated with 
the dye for 2 hours, and then media was removed and replaced with DMSO.  Color development 
in the plates, which is correlated with the metabolic activity of living cells, was read at 590nm 
using the SpectraMax M2e plate reader (Molecular Devices, Sunnyvale, CA).   
 
Pre-treatment MTT Cell Viability Assay  
HN12 and HN30 cells were seeded as described above in Co-treatment MTT Cell 
Viability Assay methods.  Cells were treated with 1) BITC (2.5-10µM) for 1-hour, 2) a 1-hour 
pretreatment of NAC followed by a 1-hour BITC (2.5-10µM) treatment, 3) NAC alone for 1-
hour, or 4) appropriate vehicle control.  All treatments were prepared in DMEM containing 
0.05% FBS, 1% P/S.  After 1-hour of treatment MTT assay was performed as described above in 
Co-treatment MTT Cell Viability Assay methods.   
 
Wound-Healing Assay 
Cell migration was determined using a wound-healing assay.  HN12 cells were cultured 
in DMEM containing 10% FBS, and 1% Pen-Strep in 6-well plates until 90% confluent, and then 
media was changed to DMEM with 0.05% FBS and 1% P/S overnight to synchronize the cells.  
A line was drawn horizontally on the bottom of each well with a permanent marker, and a plastic 
pipette tip (p200) was used to generate 3 vertical scratches per well (90 degrees to the permanent 
line).  Cell debris were washed away with PBS and initial scratch sizes were determined with an 
inverted light microscope (Olympus IX51, Center Valley, PA) at 100X magnification.  Six 
measurements were made per well, 1 below and 1 above the horizontal line for each scratch 
before treatment.  Cells were treated with 1) BITC (1.25 and 2.5μM), 2) 5mM NAC, 3) 
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2,500U/mL catalase, 4) a combination of BITC and NAC, or 5) BITC and catalase for 1 hour at 
37oC.  DMSO, at the same concentration as in the BITC treated wells, was used for the vehicle 
control.  After 1-hour, plates were washed with PBS and media was replaced with DMEM (10% 
FBS, 1% P/S).  Wound healing was analyzed 24 hours after treatment.  Images were taken at 
100X magnification, as described above, and changes in cell migration were determined by 
calculating the percent of wound healing.  Percent wound healing= ((scatcht-0hr - scatcht-
24hr)/scatcht-0hr)*100.  Experiments were repeated 3 times. 
 
MTT Cell Viability/Chemosensitivity Assay 
HN12 and HN30 cells were seeded at an initial density of 5x103 cells/well in Corning 96-
well tissue culture plates (Corning, NY) and allowed to settle overnight.  Cells were treated with 
1) BITC (5μM); 2) NAC (5mM); 3) Cisplatin (10μM); 4) co-administration of BITC (5μM) and 
NAC (5mM); 5) co-administration of cisplatin (10μM) and NAC (5mM) 6) a 1-hour 
pretreatment of BITC (5M) followed by a treatment of CDDP (10M) for 24 hours; or 7) a 1-
hour pretreatment of BITC (5M) with NAC (5mM) followed by a treatment of CDDP (10M) 
for 24 hours.  DMSO was used for the vehicle control.  Media was changed in all wells 24 hours 
after cisplatin treatment prior to the 48-hour analysis.  Cell viability was determined 24- or 48-
hours later as described above under MTT Cell Proliferation/Viability Assay methods.  Results 
were performed in technical quadruplets with three biological replicates. 
 
Statistical Analysis 
All experiments were performed at least three times as independent experiments.  
Statistical analyses were done with a multiple comparison test with appropriate post-hoc test.  
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GraphPad Prism (La Jolla, CA) was used for all statistical analysis. A p-value of <0.05 was 
considered statistically significant.   
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RESULTS 
 
BITC Increases ROS in HNSCC Cell Lines 
A dichlorofluorescein (DCF) assay indicated that BITC dramatically increased the ROS 
production in the HN12 and HN30 cell lines (p≤0.05) (Figure 4.1).  Immunofluorescence 
supported the DCF flow cytometry results and indicated that BITC treatment increased ROS in 
the HN12 cell line after 1-hour (Figure 4.2).  The percentage of HN12 cells that fluoresced after 
a 1-hour BITC treatment (2.5-10 μM) was similar, but the intensity of the DCF fluorescence was 
concentration dependent (Figure 4.2).   
We also observed that while the non-metastatic HN30 cell line showed a significant 
increase in ROS production after BITC treatment, the increase in ROS was over 3 folds greater 
in the highly metastatic HN12 cell line.  Notably, while 2.5µM BITC induced significant 
elevations in ROS in HN12 and HN30, this concentration of BITC did not induce significant 
changes in cell viability after 24 or 48 hours 
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Figure 4.1 BITC treatment significantly increases ROS in HN12 and HN30 cell lines. 
DCF assay was used to determine ROS production in HN12 and HN30 cell lines 1-hour after 
treatment with a range of concentrations of BITC (2.5-10µM).  Dark grey bars represent HN12 cell 
line. Light grey bars represent HN30 cell line.  Error bars represent standard deviation. One-Way 
ANOVA for Multiple Comparison with Dunnet’s Post-Hoc test (*p≤0.05; **p≤0.001; ***p≤0.0001). 
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Figure 4.2 Intensity of DCF fluorescence increased in HN12 cells after BITC treatment, in a dose 
dependent manner. 
Immunofluorescence was determined after a 1-hour treatment BITC (2.5-10µM).  Representative 
immunofluorescence images depict DCF immunofluorescence, which correlates to ROS production.  
Magnification 200X. 
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NAC and Catalase Attenuate BITC Induced ROS 
A dichlorofluorescein (DCF) assay showed that the ROS production induced by a 1-hour 
BITC treatment was attenuated by the addition of N-acetyl-L-cysteine (NAC) in the HN30 and 
HN12 cell line (p≤0.05) (Figure 4.3).  ROS production was also significantly inhibited by 
catalase in the HN12 and HN30 cell line (p≤0.05), but to a lesser extent than NAC (Figure 4.4). 
Interestingly, the addition of catalase to BITC treatments kept HN30’s ROS production near 
basal levels, but ROS production was markedly higher when catalase was added to BITC 
treatments in the HN12 cell line. 
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Figure 4.3 NAC inhibits BITC induced DCF fluorescence in the HN12 and HN30 
cell lines. 
DCF fluorescence was determined in the A) HN12 and B) HN30 cell line 24 hours 
after a 1-hour treatment with BITC (2.5-10µM), a 1-hour co-administration of BITC 
(2.5-10µM) and 5mM NAC, or a –hour treatment with 5mM NAC.  DCF assay was 
used to determine ROS production.  Dark grey bars represent cells treated with BITC 
only.  Light grey bars represent cells co-treated with BITC and NAC.  Error bars 
represent standard deviation.  One-Way ANOVA for Multiple Comparison with 
Dunnet’s Post-Hoc test (*p≤0.05; **p≤0.001; ***p≤0.0001). 
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Figure 4.4 Catalase inhibits BITC induced DCF fluorescence in the HN12 and HN30 cell 
lines 
DCF fluorescence in the A) HN12 and B) HN30 cell line after a 1-hour treatment with BITC 
(2.5-10µM), a 1-hour co-administration of BITC (2.5-10µM) and Catalase (2,500U/mL), or a 
1-hour treatment with Catalase (2,500U/mL) alone.  . DCF assay was used to determine ROS 
production.  Dark grey bars represent cells treated with BITC alone.  Light grey bars represent 
cells treated with BITC and Catalase.  Error bars represent standard deviation. One-Way 
ANOVA for Multiple Comparison with Dunnet’s Post-Hoc test (*p≤0.05; **p≤0.001; 
***p≤0.0001). 
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NF-κBp50 Activity Increases after BITC Treatment 
 NF-κBp50 activity was significantly in the HN12 cell line after 24 hours of 10 μM BITC 
treatment (p≤0.05) (Figure 4.5).  NF-κBp50 activity was non-significantly increased in the 
HN30 cell line after a 5 and 10 μM BITC treatment. 
 
  
Figure 4.5 NFĸBp50 activity increases in the HN12 and HN30 cell line 24hrs after BITC 
treatment. 
NFĸBp50 luminescence in the A) HN12 and B) HN30 cell line.  Cells were collected 24 hours after 
a 1-hour treatment with BITC (5-10µM).  Vehicle control was DMSO.  NFĸBp50 luminescence 
was normalized to protein concentration.  Error bars represent standard deviation.  Ctrl: negative 
control.  Veh: vehicle control.  One-way ANOVA for multiple comparisons with Dunnet’s Post-
Hoc test (*p≤0.05). 
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The Addition of either NAC or Catalase Inhibits the Cytotoxic Effects of BITC   
MTT assay results indicated that a 1-hour treatment of 5μM-10µM BITC, in DMEM with 
0.5% FBS, 1% P/S significantly decreased the cell viability of the HN12 and HN30 cell lines 
after 24 and 48 hours (p≤0.05) (Figure 4.6 A and B).  However, a 1-hour treatment of 1.25-
2.5μM BITC in DMEM with 0.5% FBS, 1% P/S did not significantly affect the cell viability of 
these HNSCC cell lines after 24 hours and 48 hours (Figure 4.6 A and B).  
Co-treatment with 5μM BITC and NAC or catalase prevented BITC from significantly 
reducing HN12 and HN30 cell viability after 24 and 48 hours (p≤0.05) (Figure 4.6 and 4.7).  
Importantly, our previous work demonstrated that treatment of the normal keratinocyte cell line 
(HAK) with 2.5-10μM BITC did not decrease viability [44,115].  This indicates that BITC is 
selectively cytotoxic against HNSCC cancer cells, and that NAC and catalase can prevent the 
toxicity of BITC in HNSCC cells.  
 
NAC Pre-treatment Followed by a BITC Treatment Decreased Cell Viability More Than 
Significantly When Compared BITC Treatment Alone 
MTT assay results indicate that a 1-hour pre-treatment with NAC followed by a 2.5 or 
5µM BITC treatment significantly increased the cytotoxic effects of BITC in HN12 and HN30 
cells (p≤0.05) (Figure 4.8 A and B).  Cell viability was determined at 24 hours post-treatment.   
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Figure 4.6 NAC co-administered with BITC prevents the effect of BITC treatments on 
HN12 and HN30 cell viability. 
MTT assay was used to determine changes in cell viability of A) HN12 or B) HN30 cell 
lines 24 hours after treatment.  Cells were treated with BITC (2.5-10µM), NAC+BITC 
(2.5-10µM), NAC, or appropriate vehicle control for 1-hour.  Percent viability was 
determined comparing absorbance of treatment groups to their respective vehicle control.  
Ctrl: negative control.  Veh: vehicle control.  Error bars represent standard deviation. One-
way ANOVA for multiple comparisons with Dunnet’s Post-Hoc test.  a= significantly 
different from Veh Ctrl (p≤0.0001); b=significantly different from 2.5μM BITC+NAC 
(p≤0.0001); c=significantly different from 5μM BITC+NAC (p≤0.0001); d=significantly 
different from Veh Ctrl (p≤0.05). 
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Figure 4.7 Catalase co-administered with BITC inhibits BITC treatment from 
reducing HN12 cell viability. 
In the HN30 cell line, co-administered BITC and Catalase does not significantly alter cell 
viability, compared to BITC treatments alone.  Cells were treated with BITC (2.5-10µM) 
for 1-hour, a Catalase (CAT) and BITC (2.5-10µM) co-treatment for 1-hour, Catalase 
alone for 1-hour, or appropriate vehicle control (VEH).  MTT assay was used to determine 
changes in A) HN12 and B) HN30 cell viability 24 hours after treatment.  Percent viability 
was determined comparing absorbance of treatment groups to their respective vehicle 
control. Error bars represent standard deviation.  One-way ANOVA for multiple 
comparisons with Dunnet’s Post-Hoc test.  a=significantly different from Veh Ctrl 
(p≤.0001); b=significantly different from 5μM BITC+ Catalase (p≤0.05); c=significantly 
different from Veh Ctrl (p≤0.05) 
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Figure 4.8 NAC pre-treatment followed by BITC treatment decreases HN12 and HN30 
cell viability more significantly than BITC treatment alone. 
Cells were treated with BITC (2.5-10µM) for 1-hour, a 1-hour pretreatment of NAC followed 
by a 1-hour treatment with BITC (2.5-10µM), NAC alone for 1-hour, or appropriate vehicle 
control.  MTT assay was used to determine changes in A) HN12 and B) HN30 cell viability 24 
hours after treatment.  Percent viability was determined comparing absorbance of treatment 
groups to their respective vehicle control. Ctrl: negative control.  Veh: vehicle control.  Error 
bars represent standard deviation. One-way ANOVA for multiple comparisons with Dunnet’s 
Post-Hoc test.  a=significantly different from Veh (p≤0.001); b=significantly different from 
2.5μM BITC (p≤0.0001); c=significantly different from Veh (p≤0.0001); d=significantly 
different from 5μM BITC (p≤0.0001). 
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NAC and Catalase Prevent BITC from Inhibiting Migration of HNSCC Cells 
A wound-healing assay indicated that BITC inhibited the migration of the highly 
metastatic HN12 cells in a dose dependent manner, after 24 hours (p≤0.05).  However, NAC 
(Figure 4.9A and B) and catalase (Figure 4.10 A and B) inhibited the ability of BITC to 
prevent wound healing in the HN12 cell line.  Under the conditions used for this assay catalase 
treatment alone appeared to increase the wound healing, although this was not statistically 
significant. 
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Figure 4.9 NAC co-administered with BITC prevents the effect of BITC 
treatments on wound healing in the HN12 cell line. 
(A) Inverted light microscope images of HN12 cells 24 hours after cells were 
treated with BITC (2.5-10µM) for 1-hour, a NAC and BITC (2.5-10µM) co-
treatment for 1-hour, NAC alone for 1-hour, or appropriate vehicle control. Dashed 
lines represent scratch size before treatment.  Magnification 100X. (B) Bar 
diagram represents the percent wound healing of the HN12 cell line 24 hours after 
treatment. Percent wound healing was calculated using wound size measurements.  
Error bars represent standard deviation. One-way ANOVA for multiple 
comparisons with Dunnet’s Post-Hoc test.  a= significantly different from Veh 
(p≤0.05); b= significantly different from 1.25μM BITC+NAC (p≤0.05); c= 
significantly different from Veh (p≤0.0001); b= significantly different from 2.5μM 
BITC+NAC (p≤0.0001). Ctrl: negative control.  Veh: vehicle control.   
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Figure 4.10 Catalase co-administered with BITC prevents the effect of BITC 
treatments on wound healing in the HN12 cell line. 
(A) Inverted light microscope images of HN12 cells 24 hours after cells were treated 
with BITC (2.5-10µM) for 1-hour, a Catalase and BITC (2.5-10µM) co-treatment for 
1-hour, Catalase alone for 1-hour, or appropriate vehicle control.  Dashed lines 
represent scratch size before treatment.  Magnification 100X.  (B) Bar diagram 
represents the percent wound healing of the HN12 cell line 24 hours after treatment. 
Percent wound healing was calculated using wound size measurements.  Error bars 
represent standard deviation.  One-way ANOVA for multiple comparisons with 
Dunnet’s Post-Hoc test.  a=significantly different from Veh (p≤0.001); 
b=significantly different from 1.25μM BITC+Catalse (p≤0.0001); c= significantly 
different from Veh (p≤0.0001); d=significantly different from 2.5μM BITC+Catalase 
(p≤0.0001). Ctrl: negative control.  Veh: vehicle control. 
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NAC Prevents BITC Induced Chemo-enhancement  
One of the major obstacles in the therapeutic use of platinum analogues is intrinsic or 
acquired resistance [100-103].  Previous work from our lab indicated that BITC treatment 
enhanced the effects of cisplatin (CDDP) in CDDP resistant HNSCC cell lines [115].  Our recent 
results suggest that when NAC is added to 1-hour pretreatment of BITC the effects typically 
induced by a pretreatment of BITC followed by CDDP are abrogated at the 24 and 48-hour time 
points in the HN12 and HN30 cell lines (p≤0.05) (Table 4.1).  
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Table 4.1 Percent viability of HN12 and HN30 cell lines 24 and 48 hours after treatment*. 
Treatment Group HN12 Cell Line HN30 Cell Line  
 24hr 48hr 24hr 48hr 
NAC 92.49 ± 8.0 c;d;e 94.04 ± 4.1 c;d;e 104.96 ± 8.3 c;d;e 82.54 ± 12.3 c;d;e 
5μM BITC 47.33 ± 5.2 a;b;d 30.24 ± 1.8 a;b;d;e 79.28 ± 7.6a;b;d 54.44 ± 6.23a;b;d 
5μM BITC +NAC 70.72 ± 5.9 a;b;c;d;e 87.85 ± 1.71 a;c;e 76.66 ± 4.5 a;b;c;d;e 89.57 ± 10.8 b;c;d;e 
5μM BITC; 10μM CDDP 30.68 ± 3.6 a;b;c;d 11.64 ± 1.49 a;b;e 41.54 ± 10.32 a;b;c;d 18.95 ± 7.6 a;b;c;d 
5μM BITC +NAC; 10μM CDDP 101.32 ± 9.2 b;c 64.71  ± 8.2 a;c;e 83.05 ± 13.8 c;e 48.08 ± 17.7 a;b;e 
10μM CDDP 70.37 ± 13.2b;c 60.58 ± 10.1 a;c;e 62.53 ± 5.5 a;b;c;d 50.33 ± 6.06 a;b;e 
NAC; 10μM CDDP 86.34 ± 12.3 b;e 64.35 ± 13.2 a;b;e 81.47 ± 12.3 b;e 52.00 ± 9.78 a;b;e 
*Percent viability ± standard deviation was calculated comparing MTT absorbance of treatment groups to their 
respective vehicle control. Cells were treated with BITC alone for 1-hour, NAC alone for 1-hour, Cisplatin (CDDP) 
alone for 24-hours, co-administration of BITC and NAC for 1-hour, NAC for 1- hour followed by CDDP for 24-
hours, a 1-hour pretreatment of BITC followed by a treatment of CDDP for 24 hours; or a 1-hour pretreatment of 
BITC and NAC followed by a treatment of CDDP (10M) for 24 hours.  a=significant difference from respective 
Vehicle Control; b=significant difference from Vehicle Control + NAC; c=significant difference from 5μM BITC; 
d=significant difference from 10μM CDDP; e=significant difference from a 5μM BITC pretreatment followed by a 
10μM CDDP 
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DISCUSSION 
 
Previous studies from our lab indicated that BITC has a dual function of targeting both 
cell viability and cell migration [44,116].  BITC, like other ITCs, targets a variety of molecular 
pathways making it difficult to pinpoint how BITC elicits its therapeutic response in HNSCC 
cells [2,116].  However, the results of the present study demonstrate that BITC induced ROS 
regulates both HNSCC cell viability and migration.  By attenuating BITC induced ROS with 
NAC and catalase we were able to inhibit BITC’s ability to prevent cell migration and add to the 
effects of cisplatin.  
NAC and catalase are both antioxidants that scavenge free radicals.  NAC is a GSH 
precursor and thereby increases cellular GSH [23,117,118].  Cellular GSH plays a central role in 
maintaining redox homeostasis, and reduced GSH act as a direct scavenger of ROS by reacting 
with singlet oxygen, hydroxyl radicals, and superoxide radicals [23].  We used NAC to 
investigate a mechanism of action of BITC in HNSCC cells.  NAC in combination with ITCs has 
been used to investigate ITC’s mechanism of action in other cell lines, and recently Gong et al. 
(2009) used NAC in combination with ITCs to support that ROS alters STAT3 activation in 
prostate cancer cells [14]. 
In our study BITC treatments significantly increased ROS production in HNSCC cell 
lines.  An increase in NF-κBp50 activity in HNSCC cells supports that the increased ROS has 
downstream effects.  However, an increase in NF-κBp50 is novel and an inhibition of NF-κBp50 
is observed in other cancer cell lines.   
BITC initiated ROS production was significantly decreased when NAC and BITC were 
co-administered.  Additionally, NAC prevented BITC induced cytotoxicity.  However, our data 
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supports that the timing of NAC administration is critical to its ability to attenuate the effects of 
BITC.  In our experiments, when NAC was administered an hour before BITC treatment its 
effects were markedly different.  NAC pretreatment enhanced BITC induced cytotoxicity.  High 
levels of cellular GSH support isothiocyanate uptake, and this could explain why pretreatment of 
NAC increases BITC induced cytotoxicity [11,105,119,120].  NAC also alters redox status in 
cells and we speculate that the pretreatment with NAC could increase the effects BITC induced 
ROS, whereas when NAC and BITC were co-administered, NAC inhibited BITC induced ROS 
[11,35,110].  This highlights the challenge of understanding the link between ROS, BITC, and 
cellular function. 
More investigation on the relationship between BITC and NAC will be needed, but the 
relationship between BITC and NAC co-administration should not be overlooked.  Regardless of 
why NAC inhibited ROS production, it is still evident that NAC prevented the therapeutic effects 
of BITC when co-administered.  This knowledge is still critical for future clinical trials.  Our 
results stress the importance of a monitoring a patient’s antioxidant consumption, because our 
data supports that administering BITC with NAC would have not been beneficial for a patient.  
Our data is also interesting because other research groups have found that NAC co-
administration enhances the effects of certain anti-cancer agents, such as retinoic acid [121,122]. 
Catalase is a scavenger of H2O2 and we used this reagent to further support the NAC 
studies.  Catalase significantly prevented BITC induced ROS production in the HNSCC cell 
lines.  The prevention of ROS production was not to the same extent as NAC, probably because 
catalase is more specific in its ROS scavenging abilities.  Catalase did, however, highlight the 
potential of H2O2 induction in HNSCC cell lines.  Furthermore, catalase alone appeared to 
increase HNSCC cell migration, which is interesting because several reports suggest that 
 92 
increasing ROS production is usually associated with increased cellular migration [112,113].  
Our results are supported by Luanpitpong et al. (2010) and because their study also showed that 
catalase stimulated cell migration while H2O2 inhibited cellular migration [114].  Inokuma et al. 
(2012) also suggest that increased ROS is pertinent to preventing lymph node metastasis in 
colorectal cancer [123].  Furthermore, Das et al. (2012) report that ROS generation inhibits EMT 
and promotes growth arrest in prostate cancer cells [124].  Taken together, our results combined 
with others indicate that investigating ROS as a whole may lead to confounding results.  Our 
results support the notion that specific types of ROS combined with the molecular pathways that 
are altered in certain cancer cells can have nontraditional results.   
In addition to preventing cellular migration we also showed that NAC and catalase 
prevented BITC induced cytotoxicity in the HNSCC cells.  NAC also prevented BITC’s ability 
to enhance the effects of the cisplatin in reducing cell viability.  The platinum compound, 
cisplatin, is regarded as one of the standard-of-care treatments for HNSCC, and is typically used 
in combination radiation or other agents [78,125,126].  Initial or acquired resistance to platinum 
compounds greatly hinder outcome for HNSCC patients and high levels of drug detoxifying 
agents are linked to cisplatin resistance [126].  Two such drug-detoxifying agents linked to 
cisplatin resistance are high levels of GSH and catalase.   
However, one way cisplatin induces cell death is by increasing ROS.  This evidence 
supports the mechanism that lower cellular ROS lead to cisplatin resistance.  Therefore, using 
NAC to increase cellular GSH and catalase to scavenge H2O2 we could be preventing the 
mechanism through which BITC enhances cisplatin toxicity. Our results showing that by 
pretreating the HNSCC cells with BITC the ROS were increased and could explain why we 
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observed increased cell death in platinum-resistant HNSCC cells pretreated with BITC followed 
by cisplatin. 
In conclusion, the present study sets the framework for future investigation into the 
mechanism through which BITC inhibits migration and invasion, as well as induces 
chemoensensitivity.  Our study suggests that ROS generation is one important mechanism by 
which BITC elicits its response.  Future studies, will work to continue to unravel the role of ROS 
in HNSCC by including experiments to evaluate the role of antioxidants, like vitamin E that 
affects the lipid bilayer, to further improve our understanding of mechanisms involved in 
chemoresistance or chemosensitivity of HNSCC cells.  Additionally, future in vivo studies will 
shed the greatest light on the potential and feasibility of BITC as an adjuvant to anti-cancer 
agent.  
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Chapter 5 : Conclusion and Future Direction 
 
In Chapter 1, we reviewed current literature on ITCs and highlighted the potential of ITC 
treatments as adjuvant cancer therapy.   We chose to specifically focus on ITC as a therapy for 
HNSCC, because, as discussed in Chapter 2 the quality of life in response to current therapy for 
advanced HNSCC is poor.  We focused specifically on BITC as an additive to current 
chemotherapy because this ITC elicited the strongest anti-tumor response in HNSCC cells.  In 
Chapter 3, we demonstrated that after 24 and 48 hours BITC treatment significantly reduced the 
viability of multiple HNSCC cell lines tested (HN12, HN8, and HN30), but not a normal 
keratinocyte line (HAK).  Treatment with BITC also decreased migration and invasion of the 
HN12 cell line and inhibited expression and altered localization of the EMT marker, vimentin.   
We also reported that a pretreatment of BITC followed by a treatment with cisplatin decreased 
HN12, HN30, and HN8 cell viability and proliferation greater than when compared to either 
treatment alone.  Pretreatment with BITC followed by a cisplatin treatment also increased 
apoptosis more than either treatment alone.  Additionally, BITC treatment decreased expression 
of the anti-apoptotic protein, bcl-2. 
Current therapies can be further improved if we understand the mechanism through 
which our treatments elicit and anti-tumor response.  In Chapter 4, we discussed how treatments 
with BITC significantly increased ROS production in HNSCC cell lines.  NAC and catalase 
attenuated this increase in ROS production.  ROS is a complex topic and presents an interesting 
paradox in cancer.  Literature supports the hypothesis that ROS can be carcinogenic or suppress 
cancer progression.  Our particular study indicates that in this model ROS production elicits and 
anti-cancer response, because at low concentrations BITC induced ROS production and limited 
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HNSCC cell migration however, when using higher concentrations of BITC, ROS decreased cell 
viability.   
Literature reveals that ITCs, including BITC, target many molecular pathways and our 
present body of work suggest that increased in ROS is one mechanism through which BITC 
treatments targets HNSCC cells.  As previously mentioned, ROS is a complex topic in relation to 
cancer therapy.  Our investigation only begins to unravel the role of ROS in HNSCC.  More 
work will be needed to fully understand the role of BITC induced ROS.  Such studies would 
incorporate other anti-oxidant products into BITC treatments.  Vitamin E is one example of an 
anti-oxidant that would increase our understanding of mechanism involved in BITC induced 
ROS in HNSCC cells, because it is a lipid soluble anti-oxidant that prevents lipid membrane 
peroxidation.  Signaling from the lipid membrane can alter many cellular functions.  Additional 
studies investigating the effect of BITC on GSH could increase our knowledge of BITC’s 
mechanism of action.  Preliminary data also suggest that studying the effect of BITC on multi-
drug transporters could highlight additional targets of BITC. 
In addition the experiments suggested above, we propose several other future studies to 
further increase our understanding of BITC’s potential as an adjuvant therapy.  Our preset 
investigation only studied one type of HNSCC therapy in conjunction with BITC.  The potential 
of BITC to add to or synergize other HNSCC therapies is high.  Developing an HNSCC animal 
model to study BITC as an adjuvant therapy will increase our understanding of BITC in an in 
vivo setting.  Future work should investigate BITC in combination with other chemotherapies as 
well as radiation therapy.   
A shortcoming of our present studies is the lack of in vivo data, however, studies by other 
groups suggest that in vitro results correlate with in vivo observations. 
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In conclusion, our present body of work supports that BITC is a promising adjuvant 
chemotherapy for HNSCC.  The studies on BITC presented in this thesis suggest that this 
therapeutic option is worth exploring on a larger scale.  Progression of our current study from 
bench to bedside will ultimately determine if inclusion of BITC as adjuvant therapy option for 
HNSCC will improve patient outcome and quality of life. 
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